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Sarcoidosis, asthma and chronic obstructive pulmonary disease (COPD) are 
inflammatory pulmonary diseases with many different clinical phenotypes. A central 
characteristic of all three diseases is the altered airway function due to inflammation. In 
sarcoidosis this is believed to be caused by a yet unidentified substance(s), in COPD 
largely by exposure to inhaled toxicants, e.g. smoking and in asthma due to an 
excessive reaction to an often harmless environmental substance. Long-term 
inflammation may cause tissue damage and in some cases irreversible destruction and 
remodelling. The current absence of a cure for these diseases points out a need to define 
the pathologic mechanisms in order to personalise treatment. 
 
In this dissertation we investigated the above mentioned diseases using global 
screening methods in combination with validation techniques. We investigated 
intracellular wingless/integrated (WNT)-signalling in bronchoalveolar lavage (BAL) 
and epithelial cells in sarcoidosis. Oxylipin levels were measured in BAL fluid of 
asthmatics. And global screening for miRNA and mRNA expression in pulmonary 
inflammatory cells in COPD, as well as miRNA in extracellular exosomes from both 
asthmatics and COPD patients, were performed. 
  
WNTs are lipoglycoproteins, important in several cellular functions such as 
proliferation and differentiation, which by binding to membrane receptors starts an 
intrecellular signalling cascade involving β-catenin. The results revealed clear 
differences in WNT expression levels in sarcoidosis patients, suggesting a role for the 
molecules in the development of fibrosis. Oxylipins are lipids synthesised on demand 
from omega-3 and omega-6 unsaturated fatty acids and involved in various 
inflammatory processes. Differing oxylipin levels in BAL fluids of mild asthmatics 
were detected in response to subway air exposure, indicating a decreased protective 
response to noxious stimuli in individuals with lowered lung function. Exosomes are 
nanosised vesicles, created in the multivesicular endosomes in various cells, believed to 
be involved in the extracellular transport of molecules. MikroRNA (miRNA), shown to 
be present in exosomes, are small RNAs capable of affecting translation of proteins 
through the regulation of mRNA. Expression of miRNAs in both cells and exosomes 
and geneexpression in the BAL cells were significantly different between smoking 
COPD patients and healthy smokers. These combined  results clearly indicates global 
changes in different signalling cascades and pathways, requiring global analysis of 
expression on multiple levels in order to elucidate mechanistic differences between the 
diseases.  
 
The projects included in this dissertation are part of larger studies. In further studies we 
aim to integrate the results from several platforms; transcriptomics, proteomics and 
metabolomics with complex analysis methods in order to elucidate the similarities, and 
more importantly, the differences between these pulmonary diseases. By doing this we 
will acquire a better understanding of the pathological reasons and further our 
understanding of these inflammatory pulmonary diseases. This may ultimately lead to 
earlier and more specific diagnostic tools, and to the development of better and more 
personal treatment options for the patients. 
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1 INTRODUCTION 
Chronic inflammatory lung diseases are an increasing global health problem [4]. In 
Europe, chronic obstructive pulmonary disease (COPD) currently causes the most lost 
work days among all respiratory illnesses [5]. In the Global Burden of Disease study, 
the World Health Organization (WHO) predicts that the prevalence of chronic lung 
disease is going to increase significantly over the next decade, and become an even 
more prominent cause of morbidity and disability worldwide [4]. Also the prevalence 
of asthma is growing globally, in particular in urban areas where polluted air is a main 
trigger of asthmatic exacerbations [6]. Sarcoidosis, however, is not as common a 
disease, with approximately 2000 new cases in Sweden yearly. The majority of patients 
recover, but some develop chronic disease with fibrosis and eventually respiratory 
failure, resulting in a mortality rate of ~5%. 
 
In the studies described here, we investigated three chronic inflammatory lung diseases, 
with some common features but also distinct differences. We approached this question 
by combining methods screening for differences at a wider scale with more traditional 
techniques, investigating molecules or proteins of interest. All of these factors can aid 
us in our search for disease-specific differences to be used in early diagnosis and 
individualised treatment, and thus improved management of inflammatory pulmonary 
disease, ultimately finding biomarkers to be used at the clinic. Biomarkers are 
biomolecule representatives for biological processes and can be used to indirectly 
measure or determine different temporal stages in a disease process. Several biomarkers 
have been suggested for the use in inflammatory lung disease, but so far only few have 




Figure 1. A schematic picture demonstrating the conducting airways from the primary bronchi to the 
distal alveoli.
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1.1 THE RESPIRATORY SYSTEM 
The respiratory system is a collective word for the anatomical system that is composed, 
in the order from proximal to distal, of the nasal cavities and the mouth, the trachea, 
bronchi, bronchioles, alveolar ducts, alveolar sacs and the alveoli (Figure 1). The main 
function of the respiratory system is to supply the body with oxygen and remove 
carbon dioxide from the tissues.  
 
The nasal cavities play an important role as a primary barrier against particulates 
entering through the air, metabolising inhaled airborne particles and for humidification 
of the breathed air. The human lungs consist of two lobes on the left side and three 
lobes on the right side. The bronchioles divide, after entering the parenchyma, 
accordingly with three branches to the right and two to the left, one into each lobe. The 
main function of the alveolar cells is to provide gas exchange between the inspired air 
and the blood in the pulmonary circulation, which occurs in the most distal alveoli [8]. 
 
The lung is a complex organ which consists of more than 40 different cell phenotypes, 
organised in a complex structure which facilitates gas exchange as well as protection 
against the surrounding environment.  
 
1.1.1 Pulmonary function measurements 
 
Pulmonary function measurements are an important indicator whether something is 
wrong with the function of the lungs. Spirometry is used to measure lung volume and 
function in order to determine whether the individual being measured has obstruction or 
restriction in their lung function. Obstructive lung disorders such as COPD are 
characterised by a reduced passage of air. The FEV1/FVC ratio is reduced due to high 
airway resistance. Patients with restrictive disorders, such as fibrosis and sarcoidosis, 
Figure 2. . Spirometry measurements demonstrating the normal tracings compared to ones from a 
patient with obstructive and restrictive pulmonary disease. 
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are prevented to expand their lungs due to an increased amount of respiratory tissue 
scarring, with a resulting reduction in TLC (Figure 2). 
 
Peak expiratory flow (PEF) refers to the maximum expiratory flow rate and can be 
measured by a handheld flow meter. Levels are lower in patients with constricted lungs. 
Normal values are dependent on the patients’ height, age and gender.  
 
 
Forced vital capacity (FVC) measures how much air you can exhale with force after 
inhaling as deeply as possible. It is a combination of tidal volume (TV), expiratory 
reserve volume (ERV) and inspiratory reserve volume (IRV) (Figure 3). 
 
Forced expiratory volume in 1 s (FEV1) is the amount of air being exhaled at the end of 
the first second of expiration. Values between 80-120% of predicted normal values are 
considered healthy. FEV1/FVC is often reported as a percentage (FEV1%). This is 
reduced in obstructive diseases such asthma, COPD, emphysema and chronic 
bronchitis.  
 
Residual volume (RV) is the air left in the airways after maximum exhalation. The 
residual volume increases quite remarkably in COPD. 
 
Total lung capacity (TLC) is the entire volume of the lungs, including RV.  
 
Tidal volume (TV) is the volume inspired or expired in one normal breath. 
 
Figure 3.  An illustration showing the lung volumes. TLC = total lung capacity, VC = vital capacity, IC 
=  inspiratory capacity, TV = tidal volume, ERV = expiratory reserve volume, IRV = inspiratory 
reserve volume, RV = residual volume. 
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1.2 CELLS TYPES OF THE LUNG 
The large bronchi contain irregularly shaped cartilaginous plates, which are absent in 
the smaller bronchi. The epithelium of the airways contains several types of cell and the 
combination of these changes along the airway. Beneath the epithelium lies the 
basement membrane, mostly consisting of collagen fibers and the submucosa. Beneath 
the basement membrane of the airway is a layer of smooth muscle. In addition, several 
types of inflammatory cells are present in the lungs at various stages. All of these cells 
are important in creating the necessary microenvironment to maintain these complex 
structures, and culturing of primary cells from the lung results in rapid de-
differentiation of the cells. This makes the use of cell lines problematic in respiratory 
research. 
 
1.2.1 The Basement membrane 
The basement membrane, on top of which the epithelium is anchored, serves several 
important roles in the lung. It acts as a barrier between the underlying mesenchymal 
compartment and the surface epithelial cells, facilitates migration and regulates the 
phenotype of epithelial cells. It consists of collagen; type IV collagen and V laminin 
present in the upper layers are secreted by the epithelial cells, type III and V collagen 
and fibronectin synthesised by subepithelial fibroblasts [9]. 
 
1.2.2 Airway epithelium  
The airway epithelium is the first barrier for airborne pollutants such as particulate 
matter, polycyclic aromatic hydrocarbons (PAHs) and oxidants present in cigarette 
smoke. In addition to the barrier function the epithelium serves a secretory function, 
producing a wide array of lipid mediators, chemokines, cytokines and growth factors 
[10-12]. Pulmonary surfactants which are composed of lipoproteins and formed by 
alveolar type II cells, maintains alveolar integrity, aiding pulmonary compliance 
(capability to expand) and plays a role in host defence. The epithelium is also an 
important source of arachidonic acid (AA) metabolites and ezymes such as 
cyclooxygenase (COX) and lipoxygenase (LOX), which are involved in mucus 
secretion, inflammation and smooth muscle tone [13]. Under normal conditions the 
airway epithelium has a capacity of regeneration and repair [14, 15]. However, during 
exposure and other foreign stimuli an imbalance can be created starting a disease 
process, which the normal system is unable to control.  
 
There are several types of epithelial cells and the composition of the airway wall 
epithelium changes from the proximal to distal airway. These cells are of three main 
types; basal cells, ciliated and secretory cells (Figure 4). The cell types in the proximal 
airways are mainly ciliated columnar and mucus secreting goblet cells. The bronchioles 
lack cartilage and glands, have thinner walls and the epithelium here mainly consists of 
ciliated columnar epithelium, only a few goblet cells are present [16]. The terminal 
bronchioles mainly consist of ciliated cuboidal cells and Clara cells. Clara cells play an 
important role in exposure to cigarette smoke, as the PAHs mainly target these cells. 
Sampling of epithelial cells from the distal airways is a very specific technique, using 
fiberoptic bronchoscopy combined with fluoroscopic guidance, unfortunately not 
available at our clinic at the time of  sample collection [17]. The epithelium in the 
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alveoli consists of two types of pneumocytes, Type I cells primarily being responsible 
for gas exchange, and Type II cells producing surfactant. The type I pneumocytes are 
the more common ones, making up two-thirds of the alveolar epithelial cells and 
covering up to 90% of the surface. 
 
Basal cells 
Basal cells are ubiquitous in the large conducting airways and there is a direct 
correlation between the thickness of the epithelium and the number of these cells. 
These cells are attached to the basement membrane and play a role in the adhesion of 
the columnar epithelium to the same [18]. Basal cells serve as stem cells giving rise to 




Ciliated cells are the main type of epithelial cell in the lung and account for about half 
of the total number of cells. These cells are covered with up to 300 cilia/cell used to 
transport mucus from the lung towards the throat. 
 
Secretory cells 
Clara cells typically extend from the basement membrane to the airway lumen, have a 
granule filled apical bulge and are present in both the bronchial and bronchiolar 
airways. They are the main secretory cells of the distal airways. Clara cells produce 
granules of surfactants, such as Clara cell secretory protein (CCSP), which cover the 
surface of the bronchial epithelium. Clara cells also have a high metabolic capacity, and 
metabolise a range of xenobiotic compounds that enter the lung through inhalation, 
such as tobacco smoke [20]. In the absence of basal cells, like in the smaller airways, 
Clara cells are able to re-differentiate into other cell types, giving rise to other types of 
epithelial cells [21]. 
 
Figure 4. Illustration showing the typical cells of the bronchial, bronchiolar and alveolar epithelium.  
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Goblet cells are characterised by secretion of mucin rich granules creating mucus for 
trapping foreign objects in the airways. The goblet cell appearance varies from the 
classical goblet shape to tall columnar cells and they have a basal nucleus [22].  
 
Normally the mucus protects the airways, maintaining hydration and trapping particles 
viruses and bacteria, as well as contributing important anti-inflammatory properties. 
The mucosal amount can be affected by exposure to noxious stimuli such as cigarette 
smoke and it is common with mucous cell hyperplasia and metaplasia, with the 
associated hypermucosis and productive cough, in inflammatory pulmonary diseases 
such as COPD [22]. The composition and consistency of the mucus also changes in 
COPD becoming more viscous due to alterations on chloride channels and destruction 
of cilia.  
 
Clara cells are capable of secreting mucins and surfactant protein (SP)-D. The 
arylhydrocarbon receptor (Ahr), a ligand activated transcription factor highly expressed 
in epithelial cells, has been implicated to mediate the effects of toxins entering the lung 
through the archidonic acid cascade and mucin production [23, 24]. COX-2 levels have 
been shown to increase upon Ahr activation [25]. The eicosanoid prostaglandin E2 
(PGE2), derived from COX-2, can activate mucin production in the airway [26].  
 
1.2.3 Inflammatory cells 
In addition to the structural cells of the lungs, a number of other cell types, such as 
inflammatory cells, migrate to and reside in the epithelium. Some of these continue to 
migrate out into the lumen. The immune system is a collection of organs, cells and 
tissue, working in a tightly regulated manner to fight foreign pathogens. The immune 
system is further divided into the innate (non-specific) immunity and the adaptive 
(specific) immunity [27].  
 
The innate immunity 
The innate immunity is the first line of defence against foreign pathogens. Danger 
signals, such as pathogen derived molecules are recognised by pattern recognition 
receptors (PRRs). The best known PRRs are toll-like receptors (TLRs). When ligands, 
such as bacteria derived DNA, lipids or double stranded RNA (dsRNA), are bound to 
these receptors it leads to an intracellular cascade involving the activation of the 
transcription factor nuclear factor κB (NF-κB). NF-κB then translocates to the nucleus 
where it initiates transcription of proinflammatory cytokines such as interleukin (IL)-
1β, IL-6 and tumour necrosis factor (TNF)-α [28].  
 
Neutrophils are involved in the initial response to pathogens and phagocytise foreign 
material. They are attracted by the cytokines IL-1β and IL-8, as well as the lipid 
mediator leukotriene B4 (LTB4). Neutrophils kill the pathogens using their intracellular 
reactive oxygen species (ROS) or by releasing granules containing enzymes that act in 
the extracellular space [29]. The levels of neutrophils are elevated in both smokers and 
COPD patients and a recent study shows increased levels of migration of neutrophils in 
smokers [30].  
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Eosinophils are attracted to the site of inflammation by the cytokines IL-3, IL-5 and 
granulocyte macrophage colony-stimulating factor (GM-CSF), as well as LTB4, 
chemokine ligand (CCL) 5 and eotaxins. Their granules contain histamine and 
eosinophilic peroxidase and they produce the cytokines IL-4, IL-5, IL-6 and IL-13 
steering the response toward a Th2 type. Therefore an increased number can be 
detected in asthma and allergies. 
 
The least common granulocyte is the basophils and normally there are very low 
amounts in human peripheral blood. Basophils contain the anticoagulant heparin and 
the vasodilator histamine, allowing better blood flow through the infected tissue.  
 
Mast cells, involved in the early allergic response, contain histamine, prostaglandin and 
leukotriene filled granules which are able to induce mucus secretion and 
bronchoconstriction [31]. Mast cells recruit other cells to the site of infection through 
indirect and direct methods through a number of cytokines and chemokines; (TNF-α, 
LTB4, IL-8, CCL2) and are involved in activating the innate immunity through IL-10, 
TNF-α, transforming growth factor (TGF)-β and histamine [32-34]. Mast cells are 
present in the airway epithelium in asthma and can be activated through TLRs by 
viral products [31, 35]. 
 
Alveolar macrophages are derived from the blood monocytes and are present in the 
alveolar lumen. They are activated by Th1 cells, as well as through TLRs, and their 
main function is to phagocytise foreign material from the body. By releasing 
chemokines such as IL-8, they also recruit other inflammatory cells to the site of 
infection, and by production of interferon (IFN)-γ they induce cluster of sifferentiation 
(CD)8+ responses and a Th1-type immunity [36]. After phagocytosis macrophages are 
capable of presenting antigens to T-cells via their major histocompatibility complex 
(MHC) molecules.  
 
Adaptive immunity 
The adaptive immune system is the secondary line of defence against pathogens. 
Among the cell types involved are T- and B-lymphocytes, both with surface receptors 
with high specificity. Each organism has its own unique set of immunologic memory 
and hence a specific combination of cells. When a cell encounters and recognises an 
antigen during e.g. an infection it leads to a clonal expansion of that specific cell to 
increase the number in order to fight the infectious agent. One subset of the cells will 
become activated, another will become memory cells with a faster reaction to the same 
antigen upon a second encounter. 
 
T-lymhocytes are developed in the bone marrow before maturing in the thymus and 
entering the blood stream and the lymphoid organs. There are two main types of T-
cells, depending on their cell surface co-receptors; CD4+ T-helper cells and CD8+ 
cytotoxic T-cells. Antigens are presented to T-cells by antigen-presenting cells through 
MHC class I to CD8+ cells and through MHC class II to CD4+ cells [37]. 
 
CD4+ T-helper cells are further differentiated into Th1 and Th2 types depending on 
what antigen they encounter and this differentiation is regulated by cytokines. IL-12 
promotes differentiation into the Th1 type, and the absence of IL-12 leads to 
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differentiation into the Th2 type. IL-4 actively drives the differentiation towards the 
Th2 development [38]. Th1 cells mainly release IFN-γ, while Th2 cells mainly produce 
IL-4, IL-5 and IL-13.  
 
CD8+ cytotoxic T-cells are involved in the protection of the host from bacteria and 
virus by the induction of apoptosis and is the predominant T cell type in COPD [39]. 
The numbers are positively correlated to the degree of emphysema and tissue 
destruction [40]. CD8+ T cells release proteolytic enzymes called perforin and 
granzymes that can cause cell death and necrosis through which they might be involved 
in the tissue destruction in COPD [39, 41].  
 
Antigen producing B-cells are responsible for the humoral immune response. The 
production of IgE antibodies by B-cells requires production of IL-4 and IL-13 from 
activated T-cells.  
 
1.3 CELLULAR SIGNALLING 
Cellular signalling is a complex system governing the events in the organism. It can be 
regarded as communication within and between cells. Through this signalling the cells 
are capable of reacting to signals from their environment and respond by creating the 
correct response for each type of stimuli. There are several types of which I will discuss 
a selected few; intracellular wingless/integrated (WNT) signalling, investigated in 
paper I in respect to the disease process in sarcoidosis; Oxylipins, shown to play a 
major role in signalling in the immune and nervous system; RNAs which are essential 
for protein synthesis, and in particular miRNAs which are capable of regulating this 
process; and finally the small vesicles called exosomes, believed to be able to transport 
signals between cells. 
 
1.3.1 WNT 
WNT signalling plays an important regulatory role in both development of the lung and 
normal lung homeostasis in the adult lung. It is believed to be involved in disease 
processes when fine tuning of repair functions have gone astray, with the persistent 
activation of proliferation leading to fibrosis and tissue destruction. A role for WNT 
signalling in different cancers, including lung cancers, is well established and a role in 
other lung diseases have been suggested [42, 43].  
  
WNTs are highly conserved lipoglycoproteins expressed in a tightly regulated 
spatiotemporal manner. To date, 19 WNT proteins have been identified in humans. 
These assign their effects through three different signalling cascades involving WNTs; 
the most conserved and well-characterised canonical WNT/β-catenin pathway, the 
WNT/CA2+ pathway signalling through calmodulin kinase II and protein kinase C, and 
finally the WNT/JNK pathway which signals through small GTPases [44]. In paper I 
we have focused on WNT/β-catenin signalling in Sarcoidosis, and this pathway will be 
the main focus. 
 
Without a WNT ligand β-catenin is bound to a destruction complex containing the 
proteins AXIN and adenomatous polyposis coli (APC), which continually 
phosphorylates the β-catenin molecule. This process requires casein kinase I (CK1) and 
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glycogen synthase kinase (GSK)-3β. The phosphorylated β-catenin is thereafter 
ubiquitinated and degraded by proteosomes.  
 
Binding of a WNT ligand to the frizzeld (FZD) and lipoprotein related protein (LRP) 
receptors on the cell surface activates a cascade where β-catenin, normally residing in 
the cytosol, is released from the degradation complex (Figure 5). This cascade contains 
the protein Dishevelled (DSH), which recruits the destruction complex of AXIN and 
APC to the plasma membrane and away from β-catenin. This step inhibits GSK-3β and 
reduces the degradation of β-catenin, allowing it to translocate to the nucleus [45]. 
 
In the nucleus β-catenin forms a complex with its DNA-binding partners known as 
lymphocyte enhancer factor (LEF)/T-cell factor (TCF) [46]. This complex then bind to 
promoters and activate target genes involved in proliferation and differentiation, such 




The most well-known profibrotic cytokine TGF-β is known to cross-talk with the 
WNT/β-catenin pathway. These pathways can promote each other’s activation and in 
some cases even co-regulate the same gene through TCF and Smad binding sites within 
the same promoter [56-60]. WNT signal activation in cell cultures with fibroblasts 
stimulates the cells to enhanced proliferation, migration and matrix production [61]. 
The initial reports of the involvement of β-catenin in fibrotic disease was the discovery 
of mutations of β-catenin and its negative regulator APC [62]. And the role for β-
Figure 5. WNT/β-catenin signalling. We hypothesised that WNT ligands secreted from inflammatory 
cells in the proximity act on cell surface FZD receptors on epithelial cells to start the signalling cascade 
that will activate β-catenin. β-catenin translocates to the nucleus where it binds to the TCF/LEF
transcription factor complex and starts the transcription of target genes. 
 10 
catenin in wound healing was demonstrated by studies in mice [63]. It is today a well 
accepted fact that repetitive injury and repair processes of the alveolar epithelium, with 
an additional local inflammation, is a central pathogenic mechanism of idiopathic 
pulmonary fibrosis (IPF) [64]. Furthermore, there is an additional impairment of the 
epithelial- mesenchymal crosstalk contributing to the pathology of IPF [65]. These and 
other studies supported the hypothesis that WNT/β-catenin signalling is involved in the 
fibroproliferative part of wound healing, as well as a role in the imbalance leading to 
disorders with fibrosis. 
 
In this thesis we have mainly focused on the above described canonical WNT/β-catenin 
pathway. Although this pathway occurs in all tissues, the genes activated are cell-type 
and context specific. Targets of WNT/β-catenin should therefore be investigated in 
individual cell types and disease states to understand the contribution of this pathway in 
the pathogenesis. 
 
Potential candidates for modulating the WNT/β-catenin pathway include siRNAs, 
antibodies against WNTs, inhibitors of GSK-3β, activators of LRP, or blocking agents 
of TCF/β-catenin interactions.  
 
The canonical WNT β-catenin pathway is down-regulated in the airway epithelium of 
both healthy smokers and smokers with COPD [66]. And it has been shown that 
activation of β-catenin attenuates the experimental emphysema in mice [67]. Abnormal 
regulation of the WNT pathway in the epithelium has been reported in smokers [66]. 
 
1.3.2 Oxylipins 
Cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 are the main 
enzymes involved in oxylipin biosynthesis in human airway epithelium [13]. There are 
four families of eicosanoids; the prostaglandins, prostacyclins, tromboxanes and 
leukotrienes. They derive from either omega-3 or omega-6 and their function 
depending on the essential fatty acid origin. Omega-6 is more pro-inflammatory, but 
both are affected by non-specific anti-inflammatory drugs (NSAIDs) and aspirin 
through down-regulation of synthesis.  
 
Mast cells metabolise arachidonic acid through the LOX and COX pathways and 
release the products leukotriene B4 (LTB4), prostaglandin E2 (PGE2) and leukotrienes 
such as LTC4 [68]. PGE2 is produced in the airway epithelium, with inhibitory effects 
on airway smooth muscle and mucus secretion, and is therefore described as a 
bronchoprotective mediator [69-72]. The complex role of PGE2 in the airways is, 
however, demonstrated by its opposing role of promoting a Th-2 bias through IL-12 
deficient dendritic cells [73]. The enzymes COX and LOX, as well as the products 5-
hydroxy eicosatetraenoic acid (HETE), 15-HETE and 12-HETE, are present in 
abundance in the airway epithelium [74, 75]. Previous studies have demonstrated 
increased amounts of 15-HETE in the epithelium of asthmatics and patients with 
chronic bronchitis [76]. Interestingly, COX-2 has been shown to be a target gene of 
WNT signalling in mice, demonstrating the complexity of these signalling pathways 
with multiple levels of regulation [53, 54]. 
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1.3.3 RNA 
A series of events, called gene expression, is required for the production of specific 
proteins or functional RNAs. Regulation of gene expression plays a crucial role in 
ensuring that the correct proteins are being translated. Regulatory events of such kind 
have cell- and tissue-specific expression patterns. There are various types of RNAs, all 
with specific roles and sizes. The information encoded in a gene is used to produce a 
specific protein through messenger RNA (mRNA). Ribosomal RNA (rRNA) forms the 
basic machinery on which the protein synthesis takes place. Transfer RNA (tRNA) 
functions as adapter RNAs, translating the information in the mRNAs into sequences of 
aminoacids to produce the protein. microRNAs (miRNA) are involved in post-
transciptional regulation of mRNA. All of these RNA transcripts combined constitute 
the trancriptome of a cell, which can be analysed using microarray based methods. 
 
mRNA 
Messenger RNA (mRNA) is a hard copy of the DNA that is being transcribed. 
Transcription describes a series of enzymatic processes that result in the transfer of 
information from the double-stranded DNA to the single-stranded mRNA, which will 
then be used as a template for protein translation. mRNAs are relatively unstable and 
easily degraded as it is only needed for a brief moment for the above described 




An ubiquitous class of RNA, microRNAs (miRNA) are relatively recently identified 
short (20-23 nt) endogenous, single-stranded nucleotides, derived from longer 
precursors called pre-miRNAs (Figure 6) [77, 78].  
 
The main function of miRNAs is to regulate gene expression and protein translation, 
and thus represent an important link between proteomic and transcriptomics/mRNA 
data. The miRNAs are relatively stable, more so than mRNA, and are known to add to 
mRNA degradation levels and also affect the protein levels by dampening the 
translation of mRNAs [79].  
 
Though previously this was thought to be their only regulatory effect, it has recently 
been discussed whether miRNAs can additionally have an up-regulatory effect on the 
mRNA [80]. The miRNAs are therefore a fundamental post-transcriptional layer that 
allows fine tuning of the regulation of gene expression. Abnormal expression patterns 
of miRNAs have been implicated in pulmonary fibrosis, COPD and asthma [81-84].  
 
Two ribonuclease-III (RNAse III) enzymes, called drosha and dicer, process the mature 
miRNA in a step-wise manner from one arm of the precursor hairpin structure. The 
other strand, called the passenger strand, previously marked miRNA* and more 
recently named   3p, has been thought to be degraded. However, recent findings suggest 
that the miRNA-3p might have a functional and active contributive role in regulation 




The nomenclatures of miRNAs changes as their function are elucidated. There is more 
to read from the name of a miRNA (example hsa-miR21a); hsa indicating it is a human 
miRNA, as opposed to mouse (mmu), rat (rno), schimpanzee (ptr) and so on. The 
number indicates the order of which they were discovered, 21 being an early discovery. 
Let-7, however, was one of the first miRNAs to be discovered and was therefore named 
prior to this system. The letter in 21a suggests that there are several closely related 
miRNAs. There are two mature products of hsa-miR-21a, miR-21a-5p and miR-21a-
3p, which was previously labelled miR-21a*, as discussed previously. 
 
1.3.4 Exosomes 
Exosomes are nanosized (30-100nm) membrane vesicles of endosomal origin, secreted 
from several different celltypes; epithelial cells, mast cells, B-cells, dendritic cells, T 
cells, macrophages and neurons [87-96]. The exosomal protein composition and the 
functions appear to differ depending on from what type of cell they originate [97]. They 
can function in antigen delivery, tolerance induction, T-cell activation and inhibition 
[95]. Exosomes can contain multiple signals, both within themselves and as surface 
receptors. Recent research has shown that exosomes can contain functional RNA 
molecules including mRNA and miRNAs, which can be shuttled from one cell to 
another, affecting the recipient cell's protein translation (Figure 7) [98-100]. The 
exosomes can consequently serve as vehicles by which a cell can communicate with 
another by delivering RNA between them and are found in physiological fluids from 
which they can be extracted. Previous analyses have been done on exosomes from 
breast milk, saliva, blood, serum, nasal secretions, urine and BALF [101-107]. 
 
Figure 6. A simplified illustration of miRNA synthesis and method of action. miRNAs are transcribed 
from genes as pri-miRNAs, whereafter they are processed by two enzymes called Drosha and Dicer. 
Exportin 5 is involved in the transport of the pri-miRNA from the nucleus to the cytoplasm. Then the 
processed miRNA duplex is cleaved by a complex of RNA-induced silencing complex (RISC) and 
argonaute (Ago) 1-4 into two strands. These single-stranded miRNAs are capable of regulating mRNA 
and protein translation. 
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Previous studies have been conducted examining exosomes in sarcoidosis and asthma 
[96, 107-109]. At the time of writing no publications could be found on exosomes in 
COPD. 
 
Chairoungdua et al. showed that WNT-signalling is down-regulated through the 
tetraspanin CD82 and CD9 control of exosomal β-catenin levels, suggesting an effect 
of exosomes on intracellular signalling [110]. 
 
 
These vesicular exosomes are not to be confused with the described exosomes involved 
in RNA processing. 
 
1.4 INFLAMMATORY PULMONARY DISEASES 
This dissertation includes studies of three inflammatory pulmonary diseases; 
sarcoidosis, asthma and COPD. Common features of these three diseases are that the 
causative mechanism for the disease process is mainly unknown, and that they are 
characterised by an ongoing inflammation in the lung leading to structural changes and 
remodelling. However, the disease processes are all different, as is the pathology and 
immune response. These are all largely heterogenous diseases with variation in the 
clinical manifestations, as well as in the disease outcome and treatment. In order to 
personalise treatment there is a pressing need to investigate and define the pathologic 
mechanisms in all three conditions more closely. Currently there is no cure to any of 
the discussed diseases and they are generally managed by oral glucocorticoids (GC) 
and/or bronchodilators as maintenance.  
Figure 7. Size comparison of exosomes to microvesicles, apoptotic bodies, virus, bacteria, platelets and 
cells. Exosomes are created by invagination into multivesicular endosomes (MVE) before being released 
into the extracellular space. Exosomes can contain miRNA. The image has been created with adjustments 




Sarcoidosis is a multisystemic inflammatory disease, characterised by non-caseating 
granulomas in various organs, commonly affecting the lungs. As opposed to other 
inflammatory lung diseases, such as COPD, bronchiolitis and emphysema, sarcoidosis 
primarily affects non-smokers [111]. Sarcoidosis has an unknown aetiology, but is 
believed to be promoted by an abnormal immune response to one or a few specific, but 
as yet unknown, environmental antigen(s). Patients display a typical accumulation in 
their lungs of activated T helper (CD4+) cells, and a CD4/CD8 ratio in bronchoalveolar 
lavage (BAL) fluid over 3.5 is considered a diagnostic indicator for sarcoidosis [112]. 
These lung-accumulated, activated CD4+ T cells have a Th1 cytokine profile, 
characterized by release of IFN-γ, TNF-α and IL-2 [113, 114]. 
 
Stage Finding 
0 Normal chest radiograph 
I Bilateral hilar lympadenopathy (BHL) 
II BHL and pulmonary infiltrations 
III Pulmonary infiltrations (no BHL) 
IV Pulmonary fibrosis 
Table 1. Chest radiographic stages in pulmonary sarcoidosis. 
Chest radiographs are used, in combination with the above mentioned CD4/CD8 ratio, 
for diagnosis of sarcoidosis. Pulmonary involvement, enlarged lymphnodes, fibrosis 
and parenchymal infiltrates can be found on the chest radiographs and the disease can 
be divided into stages depending on the appearance of these (Table 1, Figure 8). 
 
 
Figure 8. Sarcoidosis. 
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Genetic variability, especially in the form of DNA polymorphism, has been reported 
for specific phenotypes among patients with sarcoidosis [115-117]. One sub-group of 
sarcoidosis patients have Löfgren’s syndrome, defined by an acute disease onset 
combined with fever and specific symptoms such as erythema nodosum, ankle arthritis 
and bilateral hilar lymphadenopathy [118]. These patients usually have a good 
prognosis and a relatively quickly resolving disease. Patients with a chronic disease 
course are referred to as non-Löfgrens patients. 
 
It has been suggested that genetically susceptible individuals are more likely to develop 
sarcoidosis when exposed to some sort of infection or antigen. The exact pathogenic 
mechanisms have however not been resolved, and interestingly, recent microarrays on 
lung tissue and peripheral blood mononuclear cells (PBMC) revealed differentially 




Asthma is a complex inflammatory pulmonary disease affecting all ages and races. 
Currently an estimated 300 million people are affected worldwide, with the mean 
prevalence of clinical asthma of 4.9% in the Scandinavian and Baltic countries 
(Finland, Sweden, Denmark, Norway, Estonia, Iceland, Latvia, Lithuania and Poland) 
[120]. In year 2001 it was estimated as the 25th leading cause of disability [120]. 
Asthma mortality varies largely between countries, depending much on recognition of 
the disease, availability of drugs and treatment.  
 
There are many phenotypes of asthma, for example allergic (atopic) asthma and non-
allergic asthma. Allergic asthma is characterised by a Th2-dominated inflammation. 
Both phenotypes show signs of bronchial hyper-reactivity and a reversible obstruction 
of airflow. Common symptoms are wheezing, shortness of breath, chest tightness and 
cough. The cause of asthma is not fully understood, but is believed to be caused by a 
combination of environmental and genetic factors.The airway inflammation in asthma 
is primarily localised to the proximal airways, but occasionally extend to the distal lung 
and parenchyma (Figure 9) [16]. 
 
Currently there is no exact clinical or laboratorial test for diagnosing asthma. Asthma is 
diagnosed by a combination of methods and observation of symptoms. Spirometry is 
used to measure airflow limitation; an increase in FEV1 of <12% and 200 ml after 
administration of a bronchodilator is a sign of reversible airflow limitation in 
accordance to asthma. Peak expiratory flow (PEF) measurements are used to follow an 
individual’s fluctuations of measurements. Ideally the reference point will be the 
patient’s own previous measurements. A diurnal variation of >20% and an 
improvement of >20% post-bronchodilator inhalation, compared to the pre-
bronchodilator measurement, indicate asthma.  
 
Mild intermittent asthma 
Symptoms are not severe and breathing problems rarely occur. The patient manages 
asthma attacks with inhalers. FEV1 > 80%. 
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Mild persistent asthma 
As with mild intermittent asthma the symptoms are very mild and the patient can 
manage the disease by self-medicating as needed. FEV1 > 80%. 
 
Moderate persistent asthma 
Moderate asthmatics have daily symptoms and a FEV1 60 - 80%. Daily use of β2-
agonists are often required.  
 
Severe persistent asthma 
Severe asthmatics suffer from continuous symptoms, limited physical activity and a 
FEV1 < 60%.  
 
 
Figure 9. Asthma. 
Airway hyper-responsiveness (AHR) is one central feature of asthma and can be tested 
by metacholine or histamine exposure, which causes a dose-dependent drop in FEV1 
values in asthmatics. Other factors, such as dry and cold air, cigarette smoke and strong 
smells can also cause hyper-responsiveness in asthmatics, but the mechanism is 
different from the metacholine exposure. Metaholine and histamine act on smooth 
muscle receptors, while the other stimuli mainly activate the immune system [121]. 
 
Nitric oxide (NO) concentration in the breath of asthmatics is generally elevated. This 
could however also be affected by what the patient has eaten recently. Skin test allergen 
and serum IgE measurements indicate allergies and increase the probability of an 
asthma diagnosis. Atopic (allergic) asthmatics are a subgroup with hypersensitivity to 
allergens, with abnormally high levels of the IgE antibody (for review, see [122]). The 
allergens, such as pollen, animal fur and house dust mite, trigger the inflammation and 
airway obstruction in these individuals. Other environmental irritants, such as ozone 
(O3), perfume and cigarette smoke can also function as triggers.  
 
Local accumulation of eosinophils and mast cells can be observed depending on the 
sub-type of the disease. Th2 cytokines; IL-4, IL-5, IL-6, IL-10 and IL-13 levels are 
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high, leading to an inflammation and further narrowing of the airways. There is a wide 
spectrum in the severity of asthma, depending on exacerbation frequency. In asthmatics 
cytokines derived from epithelial cells, such as IL-25 and IL-33, play a role in 
orchestrating the eosinophilic airway inflammation [122]. 
 
WNTs appear to be involved, through β-catenin, in regulatory functions by preventing 
overproduction of inflammatory cytokines such as IL-6 in lipopolysaccharide (LPS) 
induced responses [123]. 
 
1.4.3 Chronic obstructive pulmonary disease 
Although the underlying causes of asthma and COPD are both inflammatory in origin, 
the aetiology and progression of the diseases are distinctly different (for review, see 
[124]). COPD primarily involves the peripheral bronchioles and the lung parenchyma, 
whereas asthma mainly affects the larger conducting airways. COPD is currently the 
12th leading cause of disability worldwide [120]. The slowly progressive airflow 
limitation in COPD leads to disability and premature death, while the variable airflow 
limitation in asthma rarely progresses in severity. 
 
A common feature in COPD is chronic bronchitis, a sputum-producing cough due to 
mucus hyper-secretion and inflammation. Symptoms often bother the patients for very 
long periods of time and is defined chronic after a total of three months in two 
consecutive years [125]. Chronic bronchitis is observed in both patients and smokers 
with normal lung function. 
 
 
Figure 10. Alveoli in healthy and COPD lungs. The image displays the enlarged alveoli and mucus 
production in COPD patients. 
Bronchiolitis, a constant inflammation of the bronchioles, leads to narrowing of the 
airways and is the main cause of obstruction [126]. Obstruction of peripheral airways 
due to inflammatory cell infiltration and fibrosis together with inflammatory exudates 
in the lumen (bronchiolitis) correlates best with the severity of the airflow obstruction 
in COPD [126]. 
 
Emphysema is characterised by the destruction of alveolar parenchyma and loss of 
alveolar septa, and can be explained as a permanent enlargement of the alveolar 
airspaces, due to destruction of the walls (Figure 10). This leads to a smaller total area 
of the alveolar epithelium, a reduced gas exchange and an elevated RV.  
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Infiltration of macrophages and T lymphocytes (mainly CD8+) is characteristic for 
COPD, with an increased number of neutrophils prevalent in patients with severe 
disease and during exacerbations [124]. Exacerbations are acute periods of worsening 
of the patient’s condition, often due to an infection or exposure to some environmental 
factor [127, 128]. COPD patients are more predisposed to infections due to the 
alterations of the tight junctions in the epithelium, allowing pathogens to enter the 
tissue more easily [129]. 
  
The number of macrophages are markedly increased (5-25 fold) in most lung 
compartments of COPD patients, and macrophages appear to play a central role in the 
pathology of COPD [130]. Airway epithelial cells are likely to play a role in the 
recruitment and differentiation of macrophages through the release of chemoattractants 
and other mediators specifically acting on macrophages. Airway epithelium changes, 
including altered ion channel regulation resulting in increased secretion and viscosity of 
mucins and defective tight junctions, stress the importance of such alterations in the 
pathogenesis of COPD [131].  
 
COPD is diagnosed using spirometry to gain lung function measurements. A post-
bronchodilator measurement ratio of FEV1/FVC below 0.7 is required for COPD 
diagnosis. Besides smoking cessation, no efficacious treatments currently exist to 
prevent the progression of COPD. The severity of COPD is divided into four stages 
according to the Global Initiative for Obstructive Lung disease (GOLD); mild (I), 
moderate (II), severe (III) and very severe (IV) [132].  
 
Stage I: Mild COPD 
At stage one the patient is usually unaware of the disease and their decline in lung 
function. There may be mild airflow limitation, as well as some symptoms like cough 
or excessive mucus production. FEV1 values are equal to or greater than 80% of the 
predicted normal values and FEV1/FVC l < 70% [132]. 
 
Stage II: Moderate COPD 
In moderate disease the airflow limitation worsens and more symptoms appear, such as 
cough, shortness of breath and sputum production. FEV1 values are between 50-80% of 
the predictive normal values and FEV1/FVC < 70% [132].  
 
Stage III: Severe COPD 
At stage III the symptoms are more prominent, with a more evident shortness of breath, 
higher degree of airflow limitation and recurrent exacerbations. FEV1 is between 30-
49% and FEV1/FVC < 70% [132].  
 
Stage IV: Very severe COPD 
At the last GOLD stage the quality of life has decreased significantly with more severe 
symptoms. The exacerbations at this stage may be life threatening. FEV1 levels are 30-
50% and FEV1/FVC < 70% [132].  
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Asthma and early stage COPD may have many symptomatic similarities, and 
traditionally the two diseases have been differentiated by whether or not the airway 
obstruction can be reversed by β2-agonists. However, this criterion is becoming more 
and more outdated as sub-categories of COPD with some reversibility are becoming 
evident [133]. This further underlines the need for better diagnostic tools. 
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1.5 ENVIRONMENTAL FACTORS 
Environmental air pollution is potentially harmful factors in the air, such as chemicals, 
particulate matter (PM) and biological material such as allergens and pathogens. These 
can be of the solid, liquid or gaseous phases. The lung epithelium is a relatively large 
surface regularly in contact with the environment and a possible means of entry for 
these harmful agents. 
 
Recent development of increased allergies and vulnerability to normally harmless 
environmental allergens supports the so called hygiene hypothesis [134]. This 
hypothesis suggests that, as levels of living standards increase, there is a decreased 
exposure to pathogenic and non-pathogenic micro-organisms. These micro-organisms 
usually promote the development of a normal immune response and an appropriate 
control of the same is refined. However, when the exposures to such infections 
decrease, the reactions to otherwise harmless environmental allergens increase. At the 
same time the levels of exposure increase due to more intense energy consumption and 
larger industrial sources. The human pulmonary system is exposed to, not only larger 
quantities, but also a more diverse mixture of pollution than before.  
 
The most abundant pollutants are PM, O3 and nitrogen dioxide (NO2). PM is composed 
of a complex mixture of solids and/or liquids varying in size, number and chemical 
composition depending on the source. O3 is a constituent of smog and is generated in a 
reaction between NO2, hydrocarbons and UV-light. The main source for PM and NO2 is 
combustion of fossil fuels, including traffic. 
 
Exacerbations of airway disease can be caused by numerous factors such as allergen 
exposure, drugs, viral infections, changes in the weather and environmental pollution 
[135]. Several studies have been conducted to investigate the effects of traffic pollution 
on inflammatory pulmonary diseases such as asthma and COPD. Greater reductions of 
FEV1 and FVC could be detected in mild to moderate asthmatics spending two hours 
walking on a heavily trafficked street in London compared to a walk in Hyde park 
[136]. Gehring et al. showed that traffic related air pollution caused an increased 
development of asthma and allergies early in life [137]. Andersen et al. showed in two 
studies that long-term exposure to traffic-related air pollution may contribute to the 
development of COPD and increase hospitalisation in asthmatics [138, 139]. 
 
All three above discussed diseases appear to be affected by external factors such as air 
pollution, allergens and antigens. Exacerbations in COPD and asthma can be caused by 
infections entering through the lung. In three of the publications, Paper II, III and IV, 
we investigated the effects of two different air pollutions; subway air and cigarette 
smoke.  
 
1.5.1 Subway air 
In many large cities, the subway system represents a major form of transportation for 
numerous individuals, yet few studies have focused on the health effects of this 
environment. 
 
The pathogenesis of asthma in urban areas is affected by multiple factors including 
PM and oxidizing agents such as O3 and nitric oxides present in polluted air. There 
are other oxidizing agents, the ones mentioned here are the main ones present in 
   21 
photochemical smog and are often regulated and used as a general measure of the 
level of air pollution. In terms of PM, the health effects most studied to date are 
related to road emissions in urban areas, which have been demonstrated to play an 
important role in asthma morbidity. 
 
Road traffic exhaust has previously been shown to affect the lung function, such as 
FEV1 and FVC in asthmatics and in healthy individuals [136, 140]. Subway 
exposures have, however, not shown these results. A study investigating particles 
collected in the London underground showed effects on A549 cell lines [141]. A 
study investigating the effect of subway air on employees working both at the level of 
the platform and above at the entry level, could not detect any short-term effects of 
the exposure on the respiratory system [142]. Klepczynska Nyström et. al.detected 
elevated expression of the T cell activation marker CD69 on both CD8+ and CD4+ 
cells after subway exposure [143, 144]. One thing in common with these exposure 
studies is that they mainly investigated the effects on respiratory function, measured 
by spirometry, as well as cell differentials and some FACS analyses, and did not 
examine effects on smaller molecules with a potentially pathological outcome.  
 
Subway air is a significant source of PM emission with physiochemical properties 
that differ drastically from that of road emission. Road emission PM is largely 
composed of PAHs, whereas subway PM generally contains more iron oxides. Given 
the potential for large-scale chronic exposure to subway air, and the cumulative risk 
for sensitive populations with compromised respiratory systems such as asthmatics, it 
is important to examine the effects of this system in greater detail. This study 
examined responses of the respiratory system to Stockholm subway air in mild 
intermittent asthmatics and healthy individuals (Papers II and III).  
 
1.5.2 Cigarette smoke 
Smoking is a common way of exposure of the lung to noxious stimuli. Cigarette smoke 
consists of 1 x 109 – 5 x 109 different toxic particles per ml [145]. The particle diameter 
size in tobacco smoke varies from 0.16 to 1.1 µm, with similar sizes observed in 
different tobacco types [146]. Generally PM1 reaches distal lung, and nanoparticles 
reach out in the blood stream to some extent, while PM10 mainly reach the proximal 
lung, or even get stuck in the nasal epithelium. The use of filters on cigarettes reduces 
the particle size slightly. Considering that the smaller particle sizes are able to cross the 
membranes and cross out into the bloodstream, thereby affecting the entire body this 
may not be a very desirable effect. Cigarettes contain for example large numbers of free 
radicals, certain ions, PAHs, nicotine, alkenes, acids, alcohols and esters just to name a 
few [145]. The exact effects of these compounds on the innate and adaptive immunity 
are largely unknown, but are believed to increase the inflammatory response and 
allergic reactions in the lungs [147]. 
  
Cigarette smoke leads to an influx of macrophages into the alveolar lumen, engulfing 
smoke particles and secreting matrix metalloproteases (MMPs) involved in tissue 
destruction. 
 
While smoking might have a protective effect on sarcoidosis, it is the main cause of 
COPD [148]. 
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2 STUDY SUBJECTS & SAMPLE COLLECTION 
 
2.1 PATIENT DATA 
2.1.1 Paper I 
A total of 48 sarcoidosis patients were recruited for this study when referred to the 
Division of Respiratory Medicine (Karolinska University Hospital, Stockholm, 
Sweden) for initial diagnostic investigation. All patients had clinical features of 
sarcoidosis evaluated by chest radiography, symptoms and pulmonary function tests. 
The patients were not on corticosteroid treatment during the study. Eighteen non-
smoking healthy control individuals, with normal lung function, were included in the 
study as controls.  
 
The BAL recovery % was significantly lower and cell concentration was significantly 
higher in sarcoidosis patients. 12 out of 48 of the sarcoidosis patients had Löfgren’s 
syndrome and 10 out of 48 were smokers. Pulmonary function tests revealed the 
expected differences, with lower VC%, FVC% and FEV1 in sarcoidosis patients 
(more details on the data can be found in paper I, table 1). The study was approved by 
the local ethics committee at Karolinska Institutet (Case number: 2005/1031-31/2). 
 
2.1.2 Papers II & III 
The patient samples collected for papers II and III were part of a larger study and more 
detail can be found in previous publications [143, 144]. 18 healthy non-smoking 
volunteers and 15 intermittent asthmatics participated in the study described in paper II. 
A sub-group of these patients, 10 healthy and 10 asthmatics, participated in the study 
described in paper III.  
 
Both populations underwent the same exposure regimen to both subway air and 
ambient office control environment in a randomised order, with a minimum of three 
weeks between. All individuals were non-smokers, non-habitual subway commuters 
(refraining from subway use altogether for 2 months prior to the study), had normal 
chest radiography, were not on corticosterioid or anti-inflammatory drug treatment and 
had no airway infections within 6 weeks of the study. β2-agonist use was allowed on 
demand.  
 
Screening for the presence of specific immunoglobulin (Ig) E antibodies against 
common inhaled allergens (Phadiatop; Pharmacia-Upjohn, Uppsala, Sweden) showed 
that 89% of the healthy volunteers had no IgE antibodies (n=16), whereas 87% 
(n=13) of the asthmatics had IgE antibodies. The asthmatics also had a positive 
reaction to a number of the radioallergosorbents (RAST, Pharmacia-Upjohn). The 
study was performed out of pollen season. 
 
All volunteers had a normal baseline FEV1. Hyper-responsiveness in asthmatics was 
tested by increasing doses of metacholine, defined as ≥20% fall in FEV1 at an 
accumulated inhalation dose of < 894 µg.  
 
Lung samples were collected through bronchoscopy, described in more detail below. 
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All volunteers participating in the study gave their informed written consent, and the 
study was approved by the Stockholm Regional Ethical Board (Case numbers 
2006/643-31/4 and 2007/748-31/3). 
 
2.1.3 Paper IV 
The samples were collected as part of a larger study called the COSMIC study 
performed at the Karolinska University Hospital encompassing a total of 120 
individuals; 40 COPD patients (later divided into a subgroup of ex-smokers), 40 
healthy current smokers and 40 healthy never smokers  with equal numbers of each 
gender. The COPD group of ex-smokers were defined as individuals who had refrained 
from smoking for at least 2 years prior to the inclusion in the study. All subjects were 
matched in terms of age (45-65 years) and gender (20/20 per group). In addition, 
COPD and healthy smokers were matched in terms of smoking history (>10 pack years, 
>10 cigarettes/day the past 6 months). The use of inhaled or oral corticosteroids was 
not allowed and subjects had no exacerbations for the last 3 months before the study. In 
order to avoid acute effects of smoking on inflammatory parameters, smokers were 
asked to refrain from smoking 8 hrs prior to bronchoscopy, which was assessed by 
exhaled carbon monoxide (CO) monitoring prior to sampling as previously described 
[149].  
 
The final number of patients included in the study is described in more detail in Table 1 
in Paper IV. Clearly degraded RNA samples and arrays with obvious experimental 
problems, such as scratches or uneven hybridisation were removed from further 
analysis. To ensure that the investigated samples were as homogenous as possible in 
regards to cell composition an additional exclusion was added. Samples with a 
macrophage percent composition of < 85% were excluded (n = 5) to assure sufficient 
enrichment of the target cell population (i.e. alveolar macrophages). A final set of strict 
exclusion criteria specifically designed for the transcriptomics analyses were applied in 
order to reduce the heterogeneity of the groups and thereby increase the statistical 
power of the study. Low recovery of BAL fluid may result in a more proximal 
sampling of the bronchoalveolar tree, resulting in a different BAL cell or exosomal 
population. As such, subjects with a recovery < 34% were excluded (n =3) [150]. 
 
All individuals underwent a thorough clinical examination with chest radiography, 
computed tomography (CT), and spirometry. The healthy never and current smokers 
had a fully normal lung function. COPD patients had mild to moderate disease (GOLD 
stage I-II, FEV1=50-100% and FEV1/FVC < 0.7). Lung function parameters from the 
spirometry were calculated as post-bronchodilator percent of predicted using the 
European Community of Coal and Steel (ECCS) normal values [151]. All subjects also 
completed an additional questionnaire on previous occupational exposure, menopause, 
hormone replacement therapy and/or other drugs, dyspnoea, fatigue, emotional function 
and occurrence of productive cough. 
 
The study was approved by the local Stockholm Regional Ethical Board (Case number 
2006/959-31/1, 2007-743-32, 2008/600-32, 2010/1064-32), and all volunteers gave their 




Bronchoscopy is a technique of visually investigating the insides of the lungs, while the 
patient is lightly sedated. During this procedure various samples, such as cells and 
biopsies, can be collected and it is used for diagnostic and therapeutic purposes. 
Bronchoalveolar lavage (BAL), performed during bronchoscopy, is a way of 
investigating inflammatory pulmonary diseases. The bronchoscope, a flexible 
fiberoptic tube is wedged into a middle-lobe bronchus and aliquots of phosphate 
buffered saline (PBS) are instilled into the lung and gently aspirated. Through BAL, 
inflammatory cells and airway exudates are collected from the distal lung, on which we 
then perform a range of analyses to characterise the patient. BAL samples from healthy 
individuals mainly contain macrophages and a small percentage of lymphocytes. The 
cell differentials can be drastically different depending on which inflammatory 
pulmonary disease the patient is suffering from, some of the changes being quite 
characteristic. Also the composition of the BAL fluid, i.e. the soluble fraction 
remaining after the inflammatory cells have been removed from the BAL, differs 
drastically in terms of the composition of inflammatory mediators depending on the 
inflammatory state of the lung. In addition to components from the epithelial lining 
fluid, the BAL fluid also contains a range of protein-, peptide-, lipid and nucleic acid 
mediators that can be used to characterise the nature of an inflammatory response or 
disease. 
 
2.2.1 BAL cells 
The cells obtained in the BAL are a mixture of inflammatory cells such as 
macrophages, lymphocytes, neutrophils and basophils. The composition of the BAL 
cells mainly depends on the disease state and whether or not there is an ongoing 
infection. The BAL fluid CD4/CD8 T cell ratio, which is elevated in sarcoidosis 
patients, is used for the clinical diagnosis of sarcoidosis. Asthmatics have increased 
eosinophil counts. Smokers have normally a larger concentration of cells than healthy 
individuals, with a large amount of macrophages and normally also increased numbers 
of neutrophils.  
 
2.2.2 BAL fluid 
After the cells are removed by centrifugation the BAL fluid remains. This fluid 
contains soluble factors and smaller vesicles, such as oxylipins and exosomes 
respectively, which are too light to have been pelleted by the low speed centrifugation 
performed for removing the cells.  
 
2.2.3 Bronchial brush biopsies 
Bronchial brush biopsies are collected during the bronchoscopy by brushing the airway 
epithelial lining with stereological brushes which are inserted through the work canal of 
the bronchoscope. One brush collects approximately 1 x 106cells and the cell 
composition of these are mainly epithelial cells (90-95%), the majority being ciliated 
cells, with some observed differences in smokers who have increased neutrophil cell 
counts. The composition of the brush biopsies is mostly due to a very proximal 
sampling location. As demonstrated in Figure 4 the composition of cells changes along 
the airways. 
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2.2.4 Exosomes 
Exosomes are present in the BALF and can be isolated through ultracentrifugation 
(discussed in more detail below). The strength in using BAL exosomes in the search of 
biomarkers is that it is less complex than serum and/or blood biomarkers. BAL samples 
also contribute greatly to knowledge of local immuno-inflammatory responses in both 
normal and disease conditions. We aim to investigate both the proteome and miRNAs 
present in exosomes and their role in the disease process. There are not as many 
miRNAs as proteins and, as mentioned above, a single miRNA may affect the 
translation of proteins from several genes.  
 
2.3 SUBWAY AIR EXPOSURE 
All individuals in paper II and III were exposed to both subway air and ambient office 
air, in a randomised order with a minimum interval of 3 weeks. The study was carried 
out outside of pollen season (mid-October to mid-March). The subjects were not 
habitual commuters and were further encouraged to refrain from using the subway 
during the study, avoid areas with high pollution and limit the amount of exercise at 
the day of exposure to the minimum. 
  
The subway air exposures were conducted during rush hour (4-6pm) at near platform 
level at a central subway station in Stockholm (Odenplan). The air in the room where 
the subway exposure took place had a corresponding quality to the air at the platform. 
Breathing was controlled by allowing the subjects use an exercise bicycle in 15 min 
interval with a resistance of 20 L/min/m2 body surface. This was to ensure that they 
would adapt mouth breathing and take deeper breaths. Control exposures were 
performed during a corresponding amount of time in a normal office environment 
with ambient clean air.  
 
The PM levels were monitored during each exposure session. Sampling of PM2.5 and 
PM10 were measured, meaning an upper cut-off of 2.5 and 10 µm respectively, with 
Harvard impactors (Air Diagnostics and Engineering Inc, Harrison, ME, USA) with 
telflon filters that were weighed after the session [143]. The measurements after these 
sessions in the subway were 77±10 and 242±40 µg·m-3 for PM2.5 and PM10 respectively 
[143]. In comparison, in a road tunnel study perfomed under the same conditions and 
with the same equipment these levels were 64 (46–81) µg·m-3and 176 (130–206) 
µg·m-3 [140]. 
 
All bronchoscopies and sample collections were performed 14 h after the 2 h exposure. 
These time points were chosen to enable comparison with a previous study 
investigating inflammatory effects after exposure to road tunnel pollution [140]. 
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3 COMMENTS ON METHODOLOGY 
3.1 SAMPLE PREPARATIONS 
3.1.1 Exosome ultracentrifugation 
In order to isolate exosomes from BALF we applied a series of centrifugations; first 
3000 x g for 30 minutes in order to remove debris, followed by an ultracentrifugation of 
10.000 x g for 30 minutes (Ultracentrifuge Beckman Coulter Optima L-100 XP 
Ultracentrifuge with Ti45 rotor) in 4°C before filtering the supernatant through a 0.2 
µm filter (DISMIC-25cs cellulose acetate, Advantec) and finally a second 
ultracentrifugation at 140.000 x g for 2 h at 4°C to pellet the exosomes. The pellet was 
resuspended directly in Nucleospin miRNA lysis reagent (Macherey-Nagel, Düren, 
Germany) and frozen at -80°C for the upcoming RNA extractions. Even with a starting 
material of 100±1 ml BALF/patient, the resulting miRNA sample amount was very 
limited. 
 
There has been some discussion about the distinction between exosomes from other 
vesicles, easily confused with exosomes, such as microvesicles, exosome-like vesicles 
and small vesicles containing virus [1]. Currently there are no specific exosome 
markers available, which complicate the extraction of a homogenous sample. The 
accepted method at the moment involves ultracentrifugation, filtration by size and using 
a sucrose gradient to separate the vesicles by density [152]. Exosomes float in sucrose 
gradients of 1.10 – 1.20 g/ml [90]. In addition, electron microscopy can be used to 
visually confirm the presence and purity of the exosomes. Exosomes express 
tetraspanins CD9, CD63, CD81 and CD 82 on their surface [153]. These can be used to 
ensure that a sample contain exosomes, but they are, however, not specific. These 
markers can be present on cells, but these have been removed from our samples and do 
not create complications for our experiment. Other vesicles with membranes from cells, 
however can also express these markers.  
 
The limited amount of sample prevented us from performing all of the above 
mentioned methods to verify the sample composition. However, the ultra-centrifugation 
protocol used here has previously been verified in other publications [103, 107, 154]. 
 
3.1.2 RNA extractions 
RNA was extracted using the NucleospinmiRNA kit (Macherey-Nagel, Düren, 
Germany) according to the manufacturer’s instructions, to separate small RNAs 
(including miRNAs) from larger RNAs before RNA integrity validation. The protein 
fraction was stored separately for further analysis in -70°C. RNA quality was assessed 
by determining UV 260/280  and 260/230 absorbance ratios obtained by the Nanodrop 
(Thermo Scientific, Wilmington, DE, USA), resulting in a mean 260/280 ratio of 1.7 
(Median 1.57). The 260 wavelength measures the absorbance of nucleic acids, 280 
measures proteins and 230 measures organic contaminants and solvents. The ratios 
between the selected combination of these give an indication of the purity of the 
measured sample. RNA size distribution was examined on RNA Pico LabChips 
(Agilent Technologies, Palo Alto, CA) processed on the Agilent 2100 Bioanalyzer 
using the small RNA electrophoresis program.  
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3.2 EXPERIMENTAL METHODS 
3.2.1 EMSA 
Electrophoretic mobility shift assay (EMSA), also referred to as gel shift assay, applied 
in paper I, is an in vitro method used to study protein-DNA interactions. Using a probe, 
a selected DNA strand of interest one can investigate whether the sequence of interest 
is present in a particular sample. The separation is performed over an electrophoretic 
charge in a polyacrylamide gel. Different molecules travel through the gel depending 
on their size and charge. In order to visualise the bands of probe-protein interactions, 
the probe can be pre-labelled with radioactivity and visualised by exposure onto a film 
[155]. In paper I we used an oligonucleotide with a TCF/LEF consensus binding site 
(5´- TGT TGT TAA GCA AAG ATC AAA GCC CGG CAG AG -3´) end-labelled 
with [γ32-P] ATP, as a probe. Alkaline phosphatase treatment is used to remove a 5´-
phosphate from the probe of choice. Thereafter polynucleotide kinase is added to 
catalyse the transfer a new phosphate group, this time a radioactively pre-labelled 




Cytocentrifugation is a technique to apply collected cells onto glass slides for further 
analyses. We used this method in paper I and paper II, for epithelial and BAL cells 
respectively. In both experiments a total of 60 000 cells/slide were cytocentrifuged onto 
SuperfrostPlus glass slides (Menzel-Gläser, Braunschweig, Germany) for further 
differential cell counts and immunocytochemistry. 
 
3.2.3 Immunocytochemistry 
In paper I and II we used immunocytochemistry to investigate the expression of 
proteins of interest in our cells. The cells, bronchial epithelial cells in paper I and BAL 
cells in paper II, were cytospun onto glass slides and specific antibodies (Ab) were used 
to target the proteins. In paper I we used the 3,3'-Diaminobenzidine (DAB) method and 
in paper II fluorescent labels conjugated to the secondary antibodies were used to 
visualise and quantify the specific binding.  
 
The slides were first fixed in formalin or paraformaldehyde (PFA) and washed in PBS 
before retrieving the antigens by boiling the slides in citrate buffer. Because these were 
whole cells, as opposed to tissue slides, we permeabilised the cell membranes by 
applying ice-cold methanol on them. After another brief wash we blocked endogenous 
peroxidise activity using hydrogen peroxide (H2O2). Unspecific binding was blocked 
using serum or antibody dilution buffer consisting of serum, bovine serum albumin 
(BSA) and TritonX. The protein of interest is bound by a primary antibody through 
incubation overnight. Incubation with the secondary antibody is briefer.  
 
In the fluorescent method the primary antibodies used were monoclonal antibodies 
against 15-LOX-1 (dilution 1:1000), peroxisome proliferator-activated receptor 
gamma (PPARγ; dilution1:100, Santa Cruz, sc-7196) produced in rabbit, and COX-
1(dilution 1:200, Invitrogen 35–8100) and COX-2 (dilution 1:200, Invitrogen 35–
8200) produced in mouse. The secondary antibody is covalently bound to a fluorescent 
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dye, which then requires a fluorescent microscope with lasers to visualise the location 
of the antigen/primary antibody binding. We used Cy5 labeled anti-rabbit sera from 
donkey (dilution 1:1000, Amersham 711-175-152) and Alexa488 labeled anti-mouse 
sera from goat (dilution 1:500– 1:1000, Molecular Probes A11001). Normal goat 
serum was purchased from Vector Laboratories (Burlingame, CA, USA; S-1000 and 
S-4000) and normal donkey serum from Sigma-Aldrich (D9663). Counterstaining was 
done using 4´,6-diamidino-2-phenylindole, dihydrochloride (DAPI, Invitrogen D1306). 
 
In the case of using horseradish peroxidase a secondary antibody conjugated with biotin 
is used and then avidin is added, creating a complex together with biotin. A DAB 
substrate is applied onto the slides converting the avidin/biotin complex into a brown 
coloured pigment visual at the location of the protein of interest. A monoclonal β-
catenin antibody was used as the primary antibody (1:100, BD Biosciences, San Jose, 
CA), the secondary antibody was a biotin-conjugated anti-mouse serum antibody 




Microarray based methods allow simultaneous semi-quantitative detection of thousands 
of transcripts from small samples. Usually this high-throughput method is used for 
hypothesis generation and the risk of cross hybridisation requires some sort of 
validation of the results. 
 
The small size and high sequence homology of miRNAs create a unique challenge for 
hybridisation-based detection techniques, requiring a different approach from the 
previous designs of genomic and mRNA methods.  
 
In this method the RNA is directly labelled with a Cy3 fluorescent dye to the 3´end of 
each RNA. RNA probes of interest are anchored to the array glass slide by a stilt. This 
probe is a synthesised sequence that will hybridise to the target RNA in the sample.  
The miRNA microarray method requires some additional steps, compared to mRNA 
arrays, due to their smaller size.The protocol used (Agilent) adds a C residue to the 
3´end during labelling of miRNAs and a G residue at the 5`end, to complement the 
previously added C residue, which increases the stability of binding target miRNAs 
[156]. The addition of these residues stabilises the annealing temperatures (Tm) of 
nearly all miRNAs to above 55°C. Tm is the temperature at which 50% of the 
oligonucleotide and its complementary strand are in duplex. The arrays we used utilise 
a calculated optimal probe length for several probes to work at the same Tm [157]. An 
additional 5´hairpin increase the target and size specificity of the miRNA. This hairpin 
structure destabilises binding to larger non-intended targets.  
 
In papers III and IV we used this technique. For miRNA expression analyses the RNA 
was labeled with Cy3-CTP using the miRNACURY LNA microRNA power labeling 
kit (Exiqon, Inc, Woburn, MA), according to manufacturers protocol. Labeled RNA 
was hybridised to one-color Agilent custom UCSF miRNA v3.5 multi-species 8x15K 
Ink-jet arrays (Agilent Technologies, Palo Alto, CA) containing 894 (paper III 
exosomes and IV BAL cells) or 1223 (paper IV exosomes) different miRNAs. Briefly, 
dephosphorylation of 5´ end was done in 37°C for 30 min followed by 95°C for 5 min 
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to stop the enzyme reaction and denature the RNA. Dye labeling of 3´ end with 
fluorochrome Cy3 was performed in a thermal cycler for 3 hrs in 16°C, 15 min 65°C 
and kept at 4°C until the next step. The reaction was stopped by blocking agent at 
100°C, thereafter samples were snap-frozen before hybridisation overnight (16 hrs) at 
55°C with a rotation of 20rpm.  
 
For the genexpression arrays (used in paper IV) RNA was amplified using the Low 
Input Quick Amplification Kit (Agilent Technologies) according to the manufacturer’s 
protocol, and subsequent Cy3-CTP labeling was performed by using one-color labeling 
kits (Agilent Technologies). Clean-up of the labeled and amplified probe was 
performed (Zymo Research Corporation, Irvine, CA). The size distribution and quantity 
of the amplified product was assessed by Nanodrop. Equal amounts of Cy3-labeled 
target were hybridised to Agilent human whole-genome 4x44K Ink-jet arrays 
containing a total of 41,000 probes corresponding to 19,596 entrez genes. 
Hybridisations were performed at 65°C for 17 hours at a rotation of 10 rpm.  
 
Arrays were washed in Agilent gene expression wash buffer 1 & 2 before scanning on 
the Agilent G2565BA scanner  (Agilent Technologies, Palo Alto, CA) with Scan 
region: Agilent HD (61x21.6) and a resolution of 5um, TIFF: 16 bit, extended dynamic 
range (XDR): 0.10. Raw signal intensities were extracted with Feature Extraction v10.1 
software (Agilent). Flagged outliers were not included in any subsequent analyses. 
 
3.2.5 PCR 
Polymerase chain reaction (PCR) is the most commonly used technique for mRNA 
detection and quantification. It is used for example for functional analysis of genes, 
DNA cloning, detection of hereditary diseases, paternity testing and forensic 
identification by genetic fingerprints and diagnosis of disease.  
 
Short DNA sequences of choice can be amplified into large quantities in a short amount 
of time. By repeated thermal cycles of heating and cooling the method allows DNA 
melting and enzymatic replication. Short DNA fragments called primers, 
complementary to the target region of interest, are used together with an enzyme called 
DNA polymerase for the amplification. These are the main components of the reaction. 
All the newly amplified strands are used in the next cycle and the DNA is thereby 
exponentially amplified.  
 
Sybr green RT-PCR 
Reverse transcription (RT) means to enzymatically convert RNA into first strand 
complementary DNA (cDNA), the substrate or template for the PCR. The method 
allows semi-quantitative detection of small amounts of template in the sample of 
interest. Real-time PCR, also called quantitative (q)PCR or qRT-PCR) is not to be 
confused with reverse-transcription PCR. In real time PCR the absolute quantity of the 
PCR product is measured during amplification, in real-time and is often combined with 
reverse transcription.  
 
In project I we used the RT-PCR method with SYBR-green fluorescence, where the 
amount of PCR product is related to the fluorescence of the reporter dye. The SYBR 
green based detection method is the least expensive PCR method. Another option is 
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TaqMan which requires additional primers and a quencher, making it a lot more 
expensive. SYBR green binds to double stranded DNA by interacting between base 
pairs and only fluoresces when bound. Measurements occur at the end of each cycle 
when the largest amount of product is present.  
 
A house-keeping gene is selected by its stability in the measured samples and 
experimental, as well as diseases, conditions. The choice of house-keeping gene for 
paper I was based on available literature defining PSMB2 as the best choice for BAL 
cells at the time of the experiments [158].  
 
After RNA extraction and measurements aliquots of total RNA were converted to 
cDNA using a kit called ReactionReady First strand cDNA synthesis kit 
(SABiosciences, Frederick, MD). We used primers for WNT5A (#PPH02410A), 
WNT7B (#PPH02464A), WNT7A (#PPH02465A) and the housekeeping gene 
PSMB2 (#PPH20109A), as well as RT2Real-Time-SYBRGreen PCR-Master Mix 
from SABiosciences. The reaction cycle was as follows: 95°C for 10 min, 95°C for 
15 s and 60°C for 1 min, for 40 cycles in an ABI PRISM Sequence Detector 7700 
(Applied Biosystems,Foster City, CA). 
 
Nano-scale qPCR 
In paper III we applied a high-throughput nano-scale technique, due to its sensitivity, to 
validate our microarray miRNA findings in exosomes, because of our limited amount of 
samples as well as due to the advancement in technology that has occurred over the few 
years passing between the two studies.  
 
In brief, we applied a multiplex quantitative RT-PCR method involving the purification 
of multiplex PCR products followed by uniplex analysis on a microfluidics chip 
(Fluidigm, South San Francisco). We validated a total of 41 miRNAs selected from our 
microarrays findings using stem-loop reverse transcription as described previously 
[159].  
 
MiRNAs and exosomes are both relatively new and unknown subjects, and there was 
not much information found on what house-keeping miRNA to use. Furthermore, 
miRNAs are not cellular samples and housekeeping genes do not exist in the same 
manner as for cells. The selection was therefore done using an algorithm called geNorm 
identifying stable endogenous miRNAs from our samples to be used for normalisation. 
Normalisation was performed by subtracting the mean of the cycle thresholds (Ct) for 
the selected house-keeping miRNAs from the Ct for a miRNA of interest, for each 
sample [160].  
 
3.2.6 FACS 
Flow cytometry, applied in paper III, is a technique used for counting cells and 
measuring expression of pre-labelled cell-surface markers. By suspending cells into 
solution, fluorescently labelling and passing them through a fluorescent detection 
monitor in a Fluorescence Activated Cell Sorter (FACS), one can determine the 
physical and chemical characteristics of the studied sample. In order to label the 
molecules of interest, specific antibodies, co-labelled with a fluorescent dye, are 
required. The FACS contains lasers with specific wavelengths that activate the 
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fluorescent dyes. These can be combined in different manner in order to sort out cells 
of interest expressing different markers.  
 
3.3 STATISTICAL METHODS 
In the use of statistical methods in omics and systems biology research, which is 
characterised by large datasets with a high number of analytes tested by relatively small 
group sizes, the pitfalls of using traditional univariate statistics become plentiful, as 
discussed in more detail below.  
 
3.3.1 Univariate analysis 
Univariate (and bivariate) methods are designed for use in smaller sets of data. When 
over 6 variables are compared, correction for the increased high positive rate should be 
considered.  
 
In paper I we used the non-parametric Mann-Whitney test to evaluate differences seen 
in the EMSA and RT-PCR data. The Mann-Whitney test, sometimes called the rank 
sum test, is a nonparametric test that compares two unpaired groups. Non-parametric 
means not assuming that the data is normally distributed. It works by ranking the values 
from low to high, paying no attention to which group each value belongs. If two values 
are the same, they both get the average of the two ranks for which they tie. The smallest 
number gets a rank of 1, the largest number a rank of N, where N is the total number of 
values in the two groups. The result is generated by summing up the ranks in each 
group. When the total sums in each group are very different, it leads to a low p value 
and a high significance of the test. 
  
Correlations between groups in paper I were performed using Spearman’s rank 
correlations test. This test is also a non-parametric test, comparing the dependence of 
two variables for each other.   
 
Analysis of fluorescent immunostaining results in paper II were done using Student’s t-
test. This test is used for data with a normal distribution, which was confirmed by 
means of Shapiro-Wilks test. 
 
Univariate statistical analyses in paper III and IV were performed using a two-way 
analysis of variance (ANOVA), and p-value correction to account for a high false 
positive rate due to multiple hypothesis testing was performed using the false discovery 
rate (FDR) method according to Benjamini- Hochberg [161]. The FDR method is a 
way of correcting for multiple comparisons. The adjustment of the p-value is based on 
a fixed proportion of expected false positives among the significant results, rather than 
a fixed statistical power as is the case for the raw p-value. 
 
False positives are the so called Type I errors, occurring when something is considered 
significant when indeed it is not. Type II errors on the other hand are called false 
negatives and appear when a statistical test fails to detect real differences. When using 
univariate methods one should consider pitfalls such as these. 
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The cost of correcting for type I errors is a loss of statistical power in the study, 
meaning the ability to detect your true positives, i.e. an increase of type II errors. 
 
ANOVA provides a statistical test comparing, like most tests, whether or not the means 
of groups are equal. But in the case of ANOVA it is possible to test several groups at a 
time, applying the t-test to more than two groups. Repeated t-tests would result in an 
increased chance of committing a type I error, which ANOVA corrects for. 
 
In paper IV a non-parametric one-way ANOVA with the Kruskal-Wallis test combined 
with Dunn’s post test was used for evaluating clinical data between the groups. The 
Kruskal-Wallis ANOVA is used for statistics comparing several unrelated groups. As 
in the Mann-Whitney method, the Kruskal-Wallis ranks the data independently of 
groups. The Kruskal-Wallis test is used for three or more groups.  
Because this test only tells whether there is a significant difference, not where it is, we 
continued with the Dunn’s post-test which gave us this information. This test compares 
the gained sum of ranks with an expected average difference, based on the number of 
comparisons and groups, reporting it then as a p value. 
 
Logarithmic (log)2 transformation of the data was applied to the data in Paper I and 
paper II, III and IV in order to acquire a normal distribution of the measured data. 
Applying a logarithmic scale hereby allows further analysis by parametric methods.  
 
3.3.2 Multivariate analysis 
An complement to univariate analysis is multivariate methods that are used for datasets 
with a larger number of variables (measurement points). The method decreases the 
dimensionality of the data to thereby aid in the interpretation and visualisation of the 
data. Multivariate modelling is a good alternative or complement to the univariate 
methods, as you avoid the problem with false positives due to a simultaneous analysis 
of all your variables and at the same time account for the co-variance of the dataset. 
 
In paper II, III and IV we had large datasets with several different measurements from 
each patient, which required more complex analytical tools. Using multivariate 
methods as a complementary method alongside the primary univariate analysis of the 
dataset, allowed us to detect more subtle changes and interactions between variables. 
Using supervised models we could reveal important differences related to other factors 
within the datasets. The multivariate findings are often also validated by univariate 
statistical testing.  
 
We performed the multivariate analyses using SIMCA P+ software v12.0.1 (Umetrics 
AB, Umeå, Sweden) using principal component analysis (PCA) and orthogonal 
projections to latent structures (OPLS) [162]. 
  
PCA analysis is an unsupervised method where the high dimensional data is reduced to 
a few dimensions, called principal components in order to visualize the data more 
clearly. As illustrated in Figure 11 the data is visualised as a cloud of dots, with one dot 
representing each observation combining the data points of all the variables for that 
particular observation. In a model with 2 PCs, the data will be visualised as a two 
dimensional image instead of a multidimensional cloud which would be impossible to 
visualise. This could be compared to a light shining on the cloud of dots. The software 
  
extracts components from
largest variance, the second largest variance becomes the 
maximal number of components is the same as the number of original variables
number of significant variables is generally limited to a few
 
In contrast to the more commonly used PCA modelling, OPLS analysis is a supervised 
method removing variation from X (descriptive variables) that a
(response variables). Separating this structured noise unrelated (orthogonal) to the 
predictive variance of interest increases the interpretability of the multivariate mo
particularly in deriving the observed group separation back to the variables of interest 
[164].  
 
Figure 11. An illustration demonstrating the method by which algorithms creates a two
image of multiple dimensions.  In the example we have
for each observation combined into one dot for each observation (A). The
is created where the variance is the largest, 
(B). When all the components explaining the data are created, the data is projected onto a plane, 
illustrated by a black dot (C). This could be compared to shining a light onto a cloud of dots and looking 
at the shadow that it creates (D). 
[163, 165]. 
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much of the variation in the data is explained, incl
the description of the consistent structure of interest. Over
it lowers the prediction quality measured by the above mentioned coefficient Q
 
Variable selection for model optimis
Variable Importance in the Projections (VIP) and scaled loadings of the predictive 
component of the OPLS models (p(corr)), using iterative selection cut
scores and p(corr) values, as displayed in the 
The inclusion criteria applied were VIP
axis). Blue colored spots indicate selection in first iteration, 
selection following a second iteration utili
 
Figure 12. A volcano plot demonstrating the selection of variables based on VIP and p(corr) values for 
optimisation of the model. 
Individual models were compared through a sh
analyses, where the scaled loadings (p(corr)) of the respective models are plotted 
against each other (Figure 13)
cluster along the diagonals, while variables unique for either model are found along the 
axes. The empty space at the center is due t
p(corr) values. 
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Figure 13. SUS-plot used to compare two models. P(corr) values from each model are plotted against each 
other. Variables around the diagonal red lines are shared structu
along the axes, i.e. in the squares are unique for one of the models.
 







The overall aims of the following projects are to, by the use of multiple platforms, 
elucidate differences and similarities in three common inflammatory pulmonary 
diseases; Sarcoidosis, asthma and COPD. In addition to results from techniques used in 
this dissertation; electrophoretic mobility shift assay (EMSA), semi quantitative RT-
PCR, immunocytochemistry, FACS and RNA microarrays, we will expand our data 
with additional proteomics and metabolomics techniques. By applying complex 
analysis methods we strive to add to the current knowledge of inflammatory pulmonary 
diseases, potentially finding biomarkers and pharmaceutical targets to be used for early 
diagnosis and individualised treatment. 
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5 RESULTS & DISCUSSION 
 
5.1 WNT SIGNALLING IN SARCOIDOSIS 
As discussed in the introductory part, WNTs are important in several physiological 
functions such as cell proliferation, differentiation and migration. Many of the target 
genes of the WNT/β-catenin pathway have been shown to be up-regulated in 
sarcoidosis [167, 168].  
 
Previous findings have shown WNTs to be important in the development of fibrosis in 
fibrotic pulmonary diseases such as idiopathic pulmonary disease (IPF) and fibrosis 
often develops in chronic sarcoidosis [167]. With this background we hypothesised that 
WNTs might play a role in sarcoidosis. More specifically we speculated that WNTs 
secreted from inflammatory cells in BAL, could be involved in the increased 
intracellular active β-catenin levels in epithelial cells and contribute to the development 
of fibrosis in the sarcoidosis patients. Epithelial cells express several WNT-receptors 
[169, 170]. 
 
In paper I we investigated the activity of β-catenin, the intracellular signalling molecule 
in the WNTs signalling cascade, in BAL cells and brush biopsy samples from 
sarcoidosis patients. We investigated the gene expression by RT-PCR in BAL cells. 
Using a radioactively marked probe with the known sequence of a TCF/LEF 
oligonucleotide on nuclear extracts prepared from the collected cells, we could by 
EMSA determine the presence of complementary binding sites. By 
immunocytochemistry we studied the nuclear expression of β-catenin in epithelial cells 
in patients with sarcoidosis, and found indications of an increased activation. 
 
WNT3, -4, -7A, -7B, -10B and -11 expressions have previously been described in lung 
and lung cell lines [170-174]. We investigated the expression of WNT3, WNT5A, 
WNT7A, WNT7B and WNT11 in BAL cells and found WNT5, WNT7A and WNT7B to 
be differentially expressed. These differences were even more pronounced when sub-
dividing the patients into groups according to disease stages (Figure 14). The levels of 
WNT3 and WNT11 were below detection levels. This suggests a role for WNTs in the 
inflammatory process in sarcoidosis and a possible role in the formation of granulomas, 
which is a characteristic feature of sarcoidosis. Abnormal WNT-signalling has 
previously been shown in idiopathic pulmonary fibrosis, with an up-regulation of 
WNT7B, WNT10B and WNT1 [175]. The later stages of sarcoidosis have elevated 
fibrosis development (Table 1) and these results support our hypothesis of WNT 
involvement in this process. 
 
Interestingly, our results indicate that the expression of WNTs in sarcoidosis may be 
affected by smoking status. This is supported by another study that showed that the 
WNT-pathway is activated by smoke in bronchial epithelial cells [176]. It would be of 
great interest to further evaluate if this is true also in COPD patients who smoke.  
The changes in WNT7B expression did not reach significance, but did, however, 
approach significance (p = 0.052) when we removed smoking individuals from the 
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sarcoidosis group (Figure 15). Smoking has previously been indicated to have a 




Figure 14. WNT expression correlated with the sarcoidosis chest radiographic stages. Semi-quantitiative 
RT-PCR levels of WNT5A, WNT7A and WNT7B mRNA in patients with sarcoidosis compared to healthy 
individuals. The Bars indicate median. H = healthy, S = sarcoidosis, I-IV = radiographic stages 1-4. 
*p<0.05. 
  
Figure 15. WNT7B expression in all included subjects compared to expression with 
sarcoidosis patients only. B
 
 
Figure 16. WNT pathway related genes differentially expressed in COPD and smokers.
= smokers, xS = ex-Smokers. Bars indic
 
 




ate median and interquartile range. *< 0.05, *** < 
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non-smoking 




By performing global analyses, the involvement of WNTs in asthma and COPD can be 
investigated in conjunction with the hypothesis generating aspects of the omics 
technologies. Unpublished results from our microarray data revealed WNT5B and 
FZD8 expression to be significantly lower in smokers and COPD smokers respectively 
(Figure 16). Other genes related to WNT signalling seen to be lower in smokers and 
COPD smokers were WNT9, WNT11, WNT7B and WNT10A, although these did not 
reach significance (Unpublished data). FZD9 expression was significantly higher in 
COPD smokers (unpublished data). 
 
Löfgrens’ syndrome is a sub-group of sarcoidosis patients with a usually good 
prognosis. Twelve of the included sarcoidosis patients had Löfgren’s syndrome. 
WNT7B expression between sarcoidosis patients with and without Löfgren’s syndrome 
reached significance (p < 0.01) (Figure 17).  
 
Several recent studies indicate that WNT5A and WNT7B are of importance also in 
asthma [177, 178].  
 
 
Epithelial-mesenchymal signalling has been implicated in IPF by several previous 
studies and some noted WNT/β-catenin to be involved in this process [167, 175, 179]. 
The inflammation in sarcoidosis involves an accumulation of T cells and macrophages, 
involved in the formation of granulomas. In the chronic disease this inflammation can 
lead to the formation of fibrosis. One possible hypothesis is that the infiltrating 
inflammatory cells involved in the pathology of sarcoidosis, much like in IPF, secrete 
mediators that start a process of epithelial-mesenchymal signalling that then becomes 
self-sustaining.  
 
Epithelial mesenchymal transition (EMT), is an important process during tissue repair, 
which has been implicated in disease pathology for both asthma and COPD [180, 181]. 
Proper lung mesenchymal growth and vascular development requires WNT7B 
signalling [182]. Mice with disrupted WNT5 displayed abnormal morphogenesis in the 
distal lung [183]. 
 
Matrix metalloproteinases (MMPs) are known gene products of WNT/β-catenin 
signalling. TGF-β may be activated through the proteolytic activities of a number of 
Figure 17.  Correlation of WNT expression with patients with and without Löfgren’s syndrome. Bars
indicate median. Non-L = Non-Löfgren’s, L = Löfgren’s.. **p<0.001. 
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mediators including MMPs. MMPs are a family of enzymes that can degrade 
components of the extracellular matrix (ECM). Deregulation of MMP activity has been 
implicated in asthma, COPD and sarcoidosis [184-191],with some differences in the 
type of MMPs present; In COPD mainly MMP-1, -2, -8 and -9, smokers with COPD 
MMP-12, sarcoidosis patients MMP-8 and -9. 
 
Recently a group investigating the expression of miRNA in lung tissue and PBMCs 
from patients with sarcoidosis found that many of the differentially expressed miRNAs, 
miRNA-25, miRNA-199-5p and miRNA-214, were involved in the regulation of TGFβ 
and WNT signalling [119].  
 
This study showed for the first time the role of WNT and β-catenin signalling in the 
pathology of sarcoidosis. The increased WNT-signal activation could contribute to the 
inflammatory processes involved in the disease. 
 
5.2 ALTERED OXYLIPIN PROFILES IN ASTHMATICS 
Although several road exposures studies have been conducted; few studies have 
investigated the effect of subway air on lung function of sensitive individuals such as 
asthmatics. Considering the vast amount of people using the subway daily, it is highly 
important to evaluate the effects of subway air on both healthy individuals, as well as 
more sensitive individuals with an already compromised lung function, such as 
asthmatics. 
 
Asthma is a chronic inflammatory lung disease that causes significant morbidity and 
mortality worldwide. Air pollutants such as PM and oxidants are important factors in 
causing exacerbations in asthmatics, and the source and composition of pollutants 
greatly affects pathological implications. 
 
Oxylipins are compounds formed from unsaturated fatty acids that play an important 
regulatory role in several processes including inflammation and immunity.  
 
In paper II we investigated responses of the respiratory system to Stockholm subway 
air in asthmatics and healthy individuals. Eicosanoids and other oxylipins were 
quantified in the distal lung to provide a measure of shifts in lipid mediators in 
association with exposure to subway air relative to ambient air. 
 
Sixty-four oxylipins representing the cyclooxygenase (COX), lipoxygenase (LOX) 
and cytochrome P450 (CYP) metabolic pathways were screened using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) of BALF. The results 
revealed divergent oxylipin profiles in asthmatics and healthy following exposure to 
ambient and subway air. Significant changes were observed in nine metabolites 
(Figure 18).  
 
The data plotted are normalised values used for calculation the actual difference 
between the exposures as a ration between subway (S) and control (C) exposures. The 
values are also log2 scaled. Oxylipin levels were increased in healthy individuals 




Validations through immunocytochemistry staining of BAL-cells were performed for 
15-LOX-1, COX-1, COX-2 and peroxisome proliferator-activated receptor gamma 
(PPARγ) (Figure 19). The majority of the significantly different oxylipins, all except 
PGE2, are metabolites from the linoleic acid (LA) or α-LA pathways. 15-LOX is an 
enzyme important in the synthesis of these metabolites. PGE2 is a COX product from 
the arachidonic acid metabolic pathway, and is the most well studied in regards to 
asthma [192]. Previous studies have indicated that some of the differentially 
expressed oxylipins are involved in the regulation of PPARγ, an anti-inflammatory 
receptor involved in several inflammatory diseases [193-196]. 
 
Figure 18. Alterations of the oxylipin profiles in response to subway air exposure. Significant differences 
(p<0.05) were observed in these 9 oxylipins. S/C = Subway Control. Values >1 indicate an increase, 
values >1 indicate a decrease. Bars indicate mean and interquartile range. Values are Log2 transformed 
and baseline normalised prior to analysis, expressed as S/C = Subway/control exposure ratio [3]. 
 
The results showed no difference between asthmatics and healthy when comparing 
the actual differences. These were calculated as a subway/control exposure ratio on 
normalised values and blotted as log2 values. When analysing the normalised data 
before ratio calculations, we could see a significant difference of COX-1 at baseline 
(control exposure) level between asthmatics and healthy (Figure 20).  
 
The observed differences indicate that asthmatics lack a protective response to 
noxious stimuli that the healthy individuals show example of in their elevated levels 
of oxylipins in response to subway air exposure. 
 
  
Figure 19. Immunocytochemistry result
asthmatics and healthy after subway exposure. S/C = subway/control exposure ratio, A= asthmatics, H= 
healthy. The bars indicate median with interquartile range 
Multivariate statistics were employed to interrogate acquired oxylipin and 
immunocytochemistry data in combination with patient clinical information. In 
Figure 21 multivariate OPLS analysis results are shown (A). 
degree of allergy response to be the variable with most weight in separating the two 
groups, asthmatics and healthy (B). 
 
Several of the altered oxylipins have known or suspected bronchoprotective or anti
inflammatory effects, sug
asthmatics following exposure to subway air. These observations may have 
ramifications for sensitive subpopulations in urban areas. 
 
Figure 20. Analysing the subway and co
between baselines (control exposures) of asthmatics and healthy. *p<0.05. C = control exposure, S = 
subway exposure. Bars indicate median with interquartile range 
 
 
s revealed a response difference approaching significance between 
[3]. 
The VIP plot reveals the 
 
gesting a possible reduced anti-inflammatory response in 
 









Figure 21. OPLS analysis integrating oxylipin, immunohistochemistry and clinical variables, with asthma 
as the y-variable. The scores plot show a strong predictive power of the model (65%), as well as a nice 
separation of the groups with only two exceptions (A). The VIP plot demonstrates the variables important 
in separating the two groups seen in the scores plot (B). Error bars indicate 95% confidence interval. 
The main differences were seen at baseline, which is interesting especially as these 
are mild intermittent asthmatics which were symptom free at the time of the study. 
When exposed to subway air the differences were levelled out. This may indicate that 
asthmatic patients have a lowered capacity to respond to noxious stimuli. 
 
 
5.3 EXOSOMAL MIRNAS IN ASTHMA AND COPD 
Exosomes have previously been shown to contain miRNAs, their presence has however 
not been demonstrated in BALF exosomes [99, 106]. We investigated the miRNA 
content of exosomes collected by ultracentrifugation from BALF from asthmatics 
(paper III) and COPD patients (paper IV), as well as in their corresponding matched 
healthy controls. In paper III we had 894 different probes and in paper IV we had 1223 
probes. This was due to an update of the array version from 3.5 to 3.6 between the two 
analyses.  
 
Exosomes, with a potential role in the pathology of inflammatory pulmonary diseases, 
may serve as transport vesicles for the small RNAs and thereby affect gene expression 
in the target cell. Not much is currently known about the packaging of exosomes, the 
selection of target cells or method of uptake by target cells. Nevertheless, it has recently 
been shown by live-cell microscopy that exosomes are taken up by cells through the 
endocytic pathway involving actin [197]. Previous studies have shown uptake of 
exosomes through phagocytosis [198]. ICAM-1(also known as CD54) bearing 
exosomes can be captured by lymphocyte function-associated protein 1(LFA1), a 
ligand for ICAM-1, expressed on CD8+ dendritic cells and activated T cells [199, 200]. 
 
Both exosomes and miRNAs have been implicated in lung homeostasis during steady-
state conditions by regulating gene expression.  
 
In paper III we characterised the miRNA content of exosomes at baseline and in 
response to subway air exposure in healthy and mild intermittent asthmatics. In paper 
IV we investigated the miRNA content in COPD smokers, COPD ex-smokers, healthy 
current smokers and healthy never-smokers.  
 
We confirmed the presence of miRNAs in exosomes from BALF in asthmatics, COPD 
patients, smokers and healthy individuals (Figure 22). We extracted RNA from the 
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exosomes in two fractions, large and small RNAs, but could not detect any large RNAs. 
Whether this is due to degradation or due to the fact that large RNAs are never 
transported by exosomes remains to be elucidated. 
 
 
Significant differences in the BALF exosomal miRNA content was revealed between 
asthmatics and healthy controls at baseline. A subset of 16 miRNAs could be used to 
classify mild, non-symptomatic asthmatics from healthy individuals with 73% 




The OPLS analysis of exosomal miRNA expression in healthy smokers and smoking 
COPD patients revealed a significant separation between the groups (CV-ANOVA p = 
Figure 22 Bioanalyzer tracings confirming the presence of small RNAs in the exosomes samples. The 
first sharp peak is a marker,small RNAs as visible directly after the marker. Any large RNAs would be 
visible as the 18S and 28S rRNA at 40 and 45 seconds (x axis).  
Figure 23. An OPLS scores plot demonstrating the separation of healthy and asthmatic individuals at 
baseline exposure (left panel). The right panel displays the 16 variables driving the separation of the two 
groups. The model is highly significant (CV-ANOVA = 1.4 * 10-5) and had a predictive power of 73% 
(R2 =0.77, Q2 = 0.73). HC = healthy control exposure, AC = asthma control exposure [3].  
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0.03), but with a few apparent outliers clustering with the opposing groups res
an overall low predictive power 
were over-expressed in smoking COPD patients compared to healthy smokers; 
miRNA-1260, miRNA-92b, miRNA
7c (Figure 24).  
 
Figure 24. OPLS scores plot of exosomal miRNAs using one orthogonal factor in a model with COPD 
smokers and healthy smokers lead to a significant model (CV
of 30%. 
 
The let-7 family of miRNAs are one of the first discovered miRNAs and are known to 
be expressed in lung tissue and cells. Let
in sputum of smoking COPD patients 
discover these miRNAs in both disease models. The otherwise differing set of miRNAs 
might be an indication of the difference between the diseases, and indeed be a clue for 
the involvement of miRNAs in the regulatio
pathology in the respective diseases. In order to use miRNAs as disease biomarkers, 
specifically selected to distinguish one inflammatory lung disease from another, we are 
in search for highly specific markers only ex
 
Whether the differential expression of miRNAs from exosomes in these two diseases 
are due to the differences between the diseases or some other yet unknown reason 
remains to be elucidated. The inflammatory cell composition and re
inflammation in these diseases are rather different. It would be of great interest to know 
the origin of the exosomes. Their surface composition and content varies depending on 
the cell type of origin and we hoped to be able to reveal the host cel
Currently there are however, no specific cell surface markers for exosomes and the 
analysis is based on a combination of markers. Tetraspanins such as CD63, CD81 and 
CD9 are expressed on the surface of exosomes, these are however not sp
merely tell us that they are exosomes, not where they originate from. Moreover, the 
expression of tetraspanins have been shown to be affected by cigarette smoke and it is 
(R2 = 0.42, Q2 = 0.30). The majority of the miRNAs 
-4286, miRNA-1181, miRNA-766, let-7b and let
-ANOVA = 0.03) with a predictive power 
-7c for example has been shown to be reduced 
[201]. With this in mind, it is not unexpected to 
n of the specific inflammatory disease 
pressed in one condition. 
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therefore questionable whether the measurements of these can be trusted when 
investigating exosomes from smokers and COPD patients [153]. 
 
We measured MHC class I and II, CD54, CD63 and CD86 by FACS in the exosomes 
from the asthma study (paper III) and found high levels of MHC class II and CD63. 
The expression of CD63 supports the endosomal origin of the vesicles. The presence of 
high MHC class II could indicate the host cells to be antigen presenting cells. But with 
CD86, also expressed by antigen presenting cells, expressed only slightly above 
background level, this theory would need further validation. CD54 (ICAM-1) is 
expressed by inflammatory cells, as well as airway epithelial cells. Although the levels 
of both CD54 and CD86 were only slightly above background levels, there were 
detectable levels which might indicate that a proportion of the exosomes originated 
from both inflammatory and epithelial cells. Furthermore, several of the miRNAs 
identified in exosomes were recent discoveries and have yet unknown functions.  
 
These two studies were not designed to be compared and one must bear in mind in the 
inter-comparison, that the matching is not perfect. The age differs significantly in the 
two study populations, with a median age of 26 years in the asthmatic study and 57 
years in the COPD study.  
 
These studies show that there are substantial differences in the exosomal miRNA 
profile between healthy individuals and unprovoked asthmatics with mild, stable 
disease, as well as individuals with COPD regardless of smoking status. 
 
5.4 MIRNA AND MRNA EXPRESSION IN BAL CELLS IN COPD 
In paper IV we also performed, in addition to the exosomal miRNA experiments 
discussed above, microarray analyses using 894 and 41,000 probes respectively for 
miRNA and mRNA analysis of BAL cells.  
 
The results revealed significant differences of the miRNA content and gene expression 
between COPD smokers and healthy smokers with normal lung function. The majority 
of the miRNAs were up-regulated in COPD smokers both in BAL cells and exosomes. 
Using multivariate statistical modelling on the BAL miRNA profiles provided a 
significant separation of the groups (p=0.004), a number of miRNAs important in 
driving the separation between healthy smokers and smokers with COPD could be 
identified. With one orthogonal and one predictive component we could achieve a 
model with R2= 0.52 and a Q2 =0.33 (Figure 25, left panel). The most prominent 
miRNA variables driving the separation of healthy smokers and smoking COPD 
patients in the BAL samples are displayed in the VIP-plot (Figure 25, right panel). The 
majority were higher in COPD patients compared to smokers, including miRNA-513b, 
miRNA-665, miRNA-664, miRNA-494, miRNA-1972, miRNA-665, miRNA-574-5p, 
miRNA-1291; while a few miRNAs were found to be down-regulated due to COPD, 
miRNA-1260, miRNA-27b and miRNA-1274a.  
 
Further analysis was performed creating gender-specific models; one for females and 
one for males, comparing smoking COPD patients to healthy smokers. The model for 
females was slightly stronger (R2 = 0.35, Q2 = 0.30, CV-ANOVA = 0.04) than the male 
model (R2 = 0.2, Q2 = 0.24, CV-ANOVA = 0.08). These differences were however not 
strong enough to draw any final conclusions about gender differences. Further analysis 
using larger groups are required. 
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Figure 25. OPLS analysis of BAL cell miRNA expression revealed 16 miRNAs important in separating 
the groups of healthy smokers and COPD smokers.
We created a similar model for the non
smokers to COPD ex-smokers, and using a SUS
important variables. This plot helped reveal miRNAs that were unique for disease; 
miRNA-1260, miRNA-24, miRNA
miRNA-664*, miRNA-612, miRNA
The BAL mRNA data showed a strong OPLS model with a clear separation between 
healthy smokers and smoking COPD patients (R
1.1*10-6, Figure 26, left panel)
XIST, RBP1, NNMT, TNNT1,
CHI3L1 (Figure 26, right panel)
mRNAs were over-expressed in COPD.
 
An important factor in the COPD disease process is inflammation and this could be 
detected by the top variables driving the separation between the groups. Some of these, 
with known roles in the inflammatory process, were let
MMP-2 and MMP-7. Other ones, such as 
migration of cells.  
 
We found that MMP-7 and osteopontin (SPP1), target genes of WNT signalling, were 
significantly differentially expressed in COPD smokers 
 
 
-smoking population, comparing healthy never
-plot investigated the correlation of 
-720, miRNA-22*, let-7b and c, miRNA
-198, miRNA-1183, miRNA-494.  
 
2
 = 0.68, Q2 = 0.63, CV ANOVA p = 
. mRNAs important for this separation were; 
 KDM5D, MMP7, IGFBP2, SPP1, ZDHHC11 
. In contrast to the miRNAs, the majority of these 
 
-7, miRNA-29b, SPP1,
NNMT are important in proliferation and 








Figure 26. OPLS analysis of gene expression between healthy smokers and COPD smokers
 
These results indicate clear differences in both miRNA and mRNA expression between 
healthy smokers and COPD smokers. The analysis method is designed to focus on 
disease related differences, instead of revealing the more expected smoking
differences, by comparing the smoking population to each other separately from the 
non-smoking population. 
translation and are capable of affecting several levels at the same time, making 
difficult to study their impact
using pathway analysis software a
interplay between the differentially expressed genes and miRNAs. Integrating these 
data with other results, such as FACS analysis data, proteomics data w
understanding of the pathology of COPD. 
 
 
MiRNAs play an important role in regulating protein 
. Further experiments verifying our results and analysis 







ill further our 
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6 CONCLUDING REMARKS 
This dissertation illustrates the complexity of the discussed diseases with many factors 
involved. Current diagnosis of the discussed inflammatory pulmonary diseases, in 
particular asthma and COPD is mainly based on a combination of lung function 
evaluation and observation of symptoms. There is no sole and exact clinical or 
laboratorial test available. This accentuates the need for a biomarkers used for specific 
and preferably early clinical markers to diagnose disease or disease phenotypes. 
 
Treatment is also currently mainly focusing on controlling inflammation and 
maintaining the diseases, and there is no cure. Unspecific systemic treatment often 
causes side effects and this calls for new medication options, possible new targets, in 
order to remove or minimise this disadvantage. 
  
The results show regulation of several pathways on multiple levels, including some 
inter-regulation between the studies molecules. Combining global analysis methods 
with complementary validation techniques in order to evaluate the similarities, or 
perhaps more importantly, the differences of these pulmonary diseases is the strength of 
this project.  
 
Recently it has been discussed that complex diseases, such as the ones discussed here, 
are likely to be due to a global change of regulation involving several factors rather that 
just singular events. The use of global screening methods from multiple molecular 
levels is therefore the preferred approach to unravel the underlying pathological 
mechanisms. Traditional so called reductionist methods are still valuable and essential, 
but rather than as a starting point, perhaps better suited as validation methods after the 
pre-selection has been made based on the global techniques. 
 
The combination of clinical phenotyping and omics methodology, bioinformatics tools 
and clinical immunology will in the larger context of the projects described here 
ultimately lead to an improved understanding of the cellular processes involved in the 
development of inflammatory pulmonary diseases. However, it should be noted that in 
order to fully evaluate the similarities and differences between the examined 
inflammatory pulmonary diseases, it might be necessary to perform all the proposed 
methodologies on all three diseases. Accordingly, this project represents a first step and 
a fraction of a larger context of elucidating the systems components underlying chronic 
inflammatory lung diseases. 
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7 FUTURE PERSPECTIVES 
With large datasets from multiple platforms, and the combined study of various 
diseases with related symptoms and manifestations, it is crucial to integrate data in 
order to benefit from all the available, disparate information. The combination of data 
from separate studies will aid us to understand the underlying reasons and differences. 
This is, however, an extensive problem in bioinformatics research. 
 
Currently there are no completed studies integrating data this way, and to this extent, 
although several attempts have been made. Data sets from different experimental 
techniques lead to a very variable set of data, requiring some sort of global scaling in 
order to include these in the same analysis. Integrating data like this from diverse and 
dynamic sources has become increasingly more demanding as the amount of data, 
sources and variability grows. 
 
The studies included in this dissertation are part of larger studies. Other sets of data 
including proteomics and metabolomics, as well as FACS analyses in addition to all the 
collected clinical patient data, on the same set of patients are already available or under 
ways. Our future aims are to complete the missing data sets, ultimately completing the 
same analysis in all three diseases, further investigating miRNA and mRNA, oxylipin 
and WNT expression in inflammatory pulmonary diseases in combination with the 
results from the other platforms. 
 
Our next challenge is therefore to integrate data from different platforms in order to 
interpret the entire data set as a whole. This rather arduous process requires further 





Sarkoidos, astma och kronisk obstruktiv lungsjukdon (KOL) är tre inflammatoriska 
lungsjukdomar med varierande kliniska fenotyper. Ett gemensamt drag för alla 
sjukdomarna är inflammationen. Vid sarkoidos tros denna inflammtion bero på 
exponering för ett eller flere ännu okända ämnen, vid KOL i de flesta fall på 
cigarrettrökning och vid astma på en överdriven reaktion mot ofarliga substanser. 
Långvariga inflammationer som dessa skadar och omformar vävnaden i lungan, i vissa 
fall oåterkalleligt. För tillfället finns inget botemedel för någon av sjukdomarna, vilket 
tyder på ett behov av att definiera de patologiska mekanismerna för en mera individuell 
behandling. 
 
I denna avhandling studerade vi ovannämnda sjukdomar genom en kombination av 
globala screeningsmetoder med valideringstekniker. Vi studerade intracellulär 
wingless/integrated (WNT)-signalering i bronchoalveolärlavage (BAL) celler och i 
epitelceller hos sarcoidos patienter. Oxylipin nivåer mättes i BAL vätska från 
astmatiker. Global screening av mRNA och miRNA utfördes i BAL celler från KOL 
patienter, samt miRNA i exosomer från både astmatiker och KOL patienter. 
 
WNT är ett lipoglykoprotein, viktig i flera cellulära processer såsom proliferation och 
differentiering genom att binda till receptorer på membranet som startar en intracellulär 
signaleringsprocess som involverar intracellulära β-catenin. Resultaten i denna 
avhandling visade att det finns skillnader i WNT uttrycket och β-catenin aktiviteten hos 
sarkoidos patienter, vilket tyder på att dessa molekyler inverkar på utvecklandet av 
fibros. Fettämnen som kallas oxylipider syntetiseras vid behov från omega-3 och 
omega-6 omättade fettsyror och är inblandade i olika inflammatoriska processer. Vi 
upptäckte skillnader i oxylipin nivåerna i BAL vätskan hos milda astmatiker 
exponerade med tunnelbaneluft, vilket antyder att individer med en sänkt lunfunktion 
har en försvagad respons till inandade skadliga stimuleringar. Exosomer är små 
vesikler, tillverkade i multivesikulära endosomer i flere olika celltyper, vilka tros vara 
involverade i extracellulär transport av molekyler. MikroRNA (miRNA), som har 
visats finnas i exosomer, är korta RNA sekvenser som kan påverka genuttrycket och  
translationen av proteiner genom att regulera budbärar RNA (mRNA). Uttrycket av 
miRNA i celler och exosomer och genuttrycket i BAL celler var signifikant olika hos 
KOL rökare jämfört med friska rökare. Dessa kombinerade resultat indikerar på globala 
förändringar i olika signaleringsvägar vilket kräver omfattande studier som tar flera 
metoders resultat i beaktande för att klarlägga de mekanistiska skillnaderna i dessa 
sjukdomar. 
 
Projekten i denna avhandling är en del av flere större studier. Vår målsättning är att 
integrera resultaten från flere tekniker; transcriptomik, proteomik och metabolomik 
genom att använda oss av komplexa analysmetoder för att klargöra de gemensamma 
dragen, samt olikheterna mellan dessa inflammatoriska lungsjukdomar. Genom större 
kännedom om bakomliggande mekanismer och orsaker för sjukdomarma, kan vi 
möjligen i framtiden framställa diagnosen tidigare och mera tydligt, och utveckla bättre 
och mera personliga behandlingsalternativ för patienterna. 
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9 TIIVISTELMÄ 
Sarkoidoosi, astma ja keuhkoahtaumatauti ovat kolme keuhkotulehdussairautta 
vaihtelevilla kliinisillä fenotyypeillä. Yhteistä näillä sairauksilla on tulehdustila, joka 
sarkoidoosissa luullaan riippuvan vielä tuntemattoman aineen alistumisesta, 
keuhkoahtaumatauti johtuu yleensä tupakoinnista ja astmaatikoilla on liioiteltu reaktio 
vaarattomille hengitetyille aineille. Yllämainitut pitkäaikaiset tulehdukset 
vahingoittavat ja muuttavat keuhkokudosta, joissain tapauksissa peruuttamattomasti. 
Tällä hetkellä parannuskeinoa ei ole, osoittaen tarpeeseen määrittää näiden sairauksien 
patologiset mekanismit johtaen henkilökohtaisempaan hoitoon. 
 
Tässä väitöskirjassa tutkittiin yllämainittua kolmea sairautta yhdistämällä laajoja 
seulontatutkimuskia validointi tekniikoilla. Tutkimme solun sisäistä wingless/integrated 
(WNT)-viestinvälitystä bronkoalveolaari (BAL) ja epiteeli soluissa 
sarkoidoosipotilaissa. Astmaatikkojen oxylipiiditasot mitatiin BAL nesteessä. Lähetti 
RNA (mRNA) ja mikroRNA (miRNA) tasoja mitatiin seulontatutkimuksilla 
keukoahtaumatautisten soluissa ja miRNA tasoja myös astmaatikoiden ja 
keuhkoahtaumatutisten exosoomeista. 
 
WNT on lipoglykoproteiini joka on tärkeä esimerkiksi solujen kasvussa ja 
eriytymisessä. WNTin solunsisäinen viestinvälitys, jossa β-cateninilla on tärkeä osa, 
alkaa sen sitoutuneen solukalvon reseptoreihin. Tulokset tässä väitöskirjassa osoittaa 
erillaisuuksia WNT tasoissa sekä solunsisäisissä β-catenin viesteissä sarkoidoosi 
potilaiden BAL ja epiteelisoluissa. Oxylipidit ovat rasva-aineita, jotka syntetisoituvat 
tarvittaessa omega-3 ja omega-6 tyydyttymättömistä rasvahapoista ja ovat osallisia 
useissa tulehduksillisissa prosesseissa. Havaittiin lievien astmaatikoiden BAL nesteen 
oxylipiidi tasoissa eroja maanalaisen metro ilman alistuksen jälkeen, ehdottaen 
keuhkosairailla olevan heikennetty vastaus hengitetyille vahingollisille aineille. 
Eksosomi on pieni vesikkeli, valmistettu solunsisäisissä endosomeissa, monissa eri 
solutyypeissä, joiden uskotaan olevan osallisia solun ulkoisessa viestinnässä kantamalla 
molekyyli viestejä kuten miRNA:ita. MiRNAt toimii transkription jälkeisinä 
geeninsäätelijöinä solussa, vaikuttamalla proteiinisynteesiin mRNA:iden kautta. 
Meidän tuloksemme osoittivat erilaisuuksia solujen mRNA ja miRNA 
ekspressiotasoissa, sekä eksosoomien miRNA tasoissa tupakoivilla 
keuhkoahtaumatautisilla potilailla verrattuna terveisiin tupakoitsijoihin. Nämä 
yhdistetyt tulokset ilmaisevat muutoksia laajalla tasolla ja monessa eri 
viestintätapahtumassa, ehdottaen tarvetta laajaan tutkimukseen, ottaen huomioon 
tuloksia monista eri tekniikoista, sillä tavalla selventäen sairauksien mekanistiset erot.  
 
Väitöskirjan osateokset ovat osia monesta suuremmasta tutkimuksesta. Tavoitteemme 
on integroida tulokset monesta eri tekniikasta; transkriptomiikasta, proteomiikasta ja 
metabolomiikasta, käyttämällä vaativia analyysimenetelmiä, selventäen yhtäläisyydet, 
sekä erillisyydet näissä kolmessa keuhkotulehdussairauksissa. Parempi tietoisuus 
mekanismeista ja sairauksien syistä on mahdollisesti tulevaisuudessa apua 
aikaisemmassa ja selvemmässä diagnoosissa, sekä kehittäessä potilaille 
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